A Phase 2 interventional study of VLA15 and Placebo in Lyme Borreliosis, sponsored by Pfizer. Completed at 19 sites in United States. Open to participants aged 5 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.
Among the 54 studies in Lyme Disease with a site in United States, this one is the 7th largest by enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2021, is one of 6 in phase 2, and was the 33rd registered.
98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.
Browse Lyme Disease studies →15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada
Ages 7+ · Healthy volunteers
Columbia University · Sites in United States
Ages 18–70
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Children's National Research Institute · Sites in United States
Ages 18+ · Women only
Children's National Research Institute · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 5 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 10
First in 1996; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 625 is above the median of 120 across 52 interventional studies indexed under Lyme Disease.
Median enrollment 72 across the 33 interventional studies, 410 across the 21 observational. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 54 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Lyme Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Lyme Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07500506Phase 3PfizerA Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | 2026-12-04 |
| NCT05776251Columbia UniversitytaVNS for Persistent Symptoms From Lyme Disease | 2026-11 |
| NCT06026969Children's National Research InstitutePregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure | 2026-12 |
| NCT06511050Icahn School of Medicine at Mount SinaiLumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | 2026-12 |
| NCT06397794Children's National Research InstituteNavigating Pregnancy and Parenthood With Lyme Disease | 2026-12-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 54 studies in Lyme Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules applying three (Month 0-2-6) or two (Month 0- 6) vaccinations. Within the study, 600 healthy subjects aged 5-65 years will be included. Subjects with a history of Lyme borreliosis (previous infection with Borrelia) as well as Borrelia naïve subjects will be enrolled. Study duration per subject will be a maximum of 50 months per subject.
VLA15-221 is a randomized, observer-blind, placebo controlled, multicenter Phase 2 study, which is set up in two parts: Main Study Phase (Part A) and Booster Phase (Part B). In Part A 600 subjects aged 5-65 years will be enrolled 1:1:1 into three groups: Group 1 will be vaccinated with VLA15 at Month 0-2-6, Group 2 will be vaccinated with VLA15 at Month 0-6 and with placebo at Month 2 and Group 3 will be vaccinated with placebo at Month 0-2-6. In Part B all eligible subjects will receive booster injections with VLA15 or placebo at Month 18, 30 and 42.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Parent(s)/legal representative(s) and subject understand the study and its procedures, agree to its provisions
If subject is of : Subject has a negative serum pregnancy test at screening (Visit 0) and agrees to employ adequate measures according to following timelines:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: VLA15 at Month 0, 2 and 6 Part B: VLA15 at Month 18, 30 and 42
Biological: VLA15
Part A: VLA15 at Month 0 and 6, placebo at Month 2 Part B: VLA15 at Month 18, 30 and 42
Biological: VLA15 · Biological: Placebo
Part A: Placebo at Month 0, 2 and 6 Part B: Placebo at Month 18, 30 and 42
Biological: Placebo
a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
PBS (Phosphate Buffered Saline)
Percentage of Participants With Solicited Local and Solicited Systemic Adverse Events (AEs) Within 7 Days After Vaccination 1
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness meeting grading scale (MGS), swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
Time frame: From Day 1 to Day 7 after vaccination 1 at Month 0
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
Time frame: From Day 1 to Day 7 after vaccination 2 at Month 2
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
Time frame: From Day 1 to Day 7 after vaccination 3 at Month 6
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Any Vaccination During the Main Study Phase
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
Time frame: From Day 1 to Day 7 after any vaccination 1, 2 or 3 at Month 0, 2 and 6, respectively
Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) Against Each Outer Surface Protein A (OspA) Serotype (ST1 to ST6) at Day 208 During the Main Study Phase
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay at Day 208 was presented in this outcome measure.
Time frame: At Day 208 (Month 7)
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 1 Booster Dose
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
Time frame: From Day 1 to Day 7 after vaccination 1 booster dose at Month 18
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 2 Booster Dose
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
Time frame: From Day 1 to Day 7 after vaccination 2 booster dose at Month 30
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Vaccination 3 Booster Dose
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
Time frame: From Day 1 to Day 7 after vaccination 3 booster dose at Month 42
Percentage of Participants With Serious Adverse Events (SAEs)
A SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition.
Time frame: From Day 1 of vaccination 1 up to 6 months following the last booster dose (up to Month 48)
Percentage of Participants With Adverse Events of Special Interest (AESIs)
An AESI (serious or non-serious) was one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor were appropriate.
Time frame: From Day 1 of vaccination 1 up to 6 months following the last booster dose (up to Month 48)
Percentage of Participants With Unsolicited AE
An AE was any untoward medical occurrence in a participant administered an investigational product, whether or not related to this treatment. Unsolicited AEs were defined as any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event.
Time frame: Up to 28 Days after vaccination 1, 2 or 3 at Month 0, 2 and 6, respectively, and up to 28 Days after vaccination 1, 2 or 3 booster dose at Month 18, 30 and 42, respectively
Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group
Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs stratified by age group 5-11, 12-17 and 18-65 years were reported. SAE: any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition. AESI: scientific and medical concern specific to the sponsor's product or program. Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AEs: any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event.
Time frame: SAEs & AESIs: From Day 1 of vaccination up to Month 48; Solicited AEs: from Day 1 to Day 7 after vaccination 1, 2, 3, 4, 5 and 6; Unsolicited AEs: up to 28 Days after vaccination 1, 2, 3, 4, 5 and 6
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) at Baseline, Days 85, 180, 365 and Month 18
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay were evaluated.
Time frame: Baseline; Days 85, 180 and 365; Month 18
Seroconversion Rate (SCR) at Days 85, 180, 208, 365 and Month 18
Seroconversion for enzyme linked immunosorbent assay (ELISA) was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a greater than or equal to (\>=) 4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.
Time frame: Days 85, 180, 208 and 365; Month 18
Geometric Mean of the Fold Rise (GMFR) for IgG When Compared to Baseline Against Each OspA Serotype (ST1 to ST6) at Days 85 and 208
GMFR for IgG when compared to baseline against each OspA serotype ST1 to ST6, determined by IgG binding assay at Day 85 and Day 208 were evaluated.
Time frame: Days 85 and 208
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Baseline, Days 85, 180, 194, 365 and Month 18
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay stratified by age group (5-11, 12-17 and 18-65 years) were evaluated. Day 194 data was reported for adult participants only as pre-specified in protocol.
Time frame: Baseline; Days 85, 180, 194 (18 to 65 years only) and 365; Month 18
SCR Stratified by Age Group at Days 85, 180, 194, 208, 365 and Month 18
Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA. Day 194 data was reported for adult participants only as pre-specified in protocol.
Time frame: Days 85, 180, 194 (18 to 65 years only), 208 and 365; Month 18
GMFR for IgG When Compared to Baseline Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Days 85 and 208
GMFR for IgG when compared to baseline against each OspA serotype ST1 to ST6, stratified by age group (5-11, 12-17 and 18-65 years) determined by IgG binding assay at Day 85 and Day 208 were evaluated.
Time frame: Days 85 and 208
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay were evaluated.
Time frame: Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
SCR at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.
Time frame: Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
GMFR for IgG Against Each OspA Serotype (ST1 to ST6) at Months 19, 31 and 43 During the Booster Phase
GMFRs for IgG were determined by IgG binding assay for each OspA serotype (ST1-ST6) at Months 19, 31, and 43 relative to the corresponding pre-booster timepoints Months 18, 30, and 42, respectively.
Time frame: Months 19, 31 and 43
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay stratified by age group (5-11, 12-17 and 18-65 years) were evaluated.
Time frame: Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
SCR Stratified by Age Group at Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.
Time frame: Months 18, 19, 23, 26, 30, 31, 39, 42, 43 and 48
GMFR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group at Months 19, 31 and 43 During the Booster Phase
GMFRs for IgG were determined by IgG binding assay for each OspA serotype (ST1-ST6), stratified by age group (5-11, 12-17 and 18-65 years) at Months 19, 31, and 43 relative to the corresponding pre-booster timepoints Months 18, 30, and 42, respectively.
Time frame: Months 19, 31 and 43
| Milestone | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| Started | 208 | 209 | 208 |
| Completed | 128 | 118 | 113 |
| Not completed | 80 | 91 | 95 |
| Withdrew: Adverse event | 1 | 1 | 4 |
| Withdrew: Withdrawal by subject | 20 | 17 | 18 |
| Withdrew: Physician decision | 7 | 9 | 10 |
| Withdrew: Moved from study area | 7 | 7 | 10 |
| Withdrew: Lost to follow-up | 26 | 27 | 29 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Other | 18 | 28 | 24 |
| Withdrew: Individual stopping criteria reached | 0 | 2 | 0 |
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness meeting grading scale (MGS), swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Pain | 61.0 (52.1 to 69.1) | 52.8 (43.4 to 61.9) | 12.6 (8.7 to 17.9) | 60.3 (55.4 to 65.0) | 44.5 (40.6 to 48.5) |
| Tenderness | 80.5 (72.6 to 86.5) | 80.7 (72.3 to 87.0) | 19.6 (14.7 to 25.7) | 81.6 (77.5 to 85.0) | 61.2 (57.3 to 65.0) |
| Erythema/Redness MGS | 10.0 (5.8 to 16.7) | 10.1 (5.7 to 17.2) | 2.5 (1.1 to 5.8) | 13.1 (10.1 to 16.7) | 9.6 (7.5 to 12.2) |
| Swelling MGS | 5.9 (2.9 to 11.6) | 4.6 (2.0 to 10.3) | 0.5 (0.1 to 2.8) | 9.1 (6.7 to 12.4) | 6.2 (4.6 to 8.5) |
| Induration/Hardening MGS | 9.2 (5.2 to 15.8) | 3.7 (1.4 to 9.1) | 1.0 (0.3 to 3.6) | 8.8 (6.4 to 12.0) | 6.2 (4.6 to 8.5) |
| Headache | 27.3 (20.1 to 35.8) | 23.1 (16.2 to 31.9) | 19.6 (14.7 to 25.7) | 23.4 (19.5 to 27.8) | 22.1 (19.0 to 25.7) |
| Muscle pain | 36.4 (28.3 to 45.2) | 33.0 (24.9 to 42.3) | 11.1 (7.4 to 16.2) | 35.6 (31.0 to 40.4) | 27.5 (24.0 to 31.2) |
| Joint pain | 10.7 (6.4 to 17.5) | 3.7 (1.4 to 9.1) | 6.0 (3.5 to 10.2) | 7.8 (5.6 to 10.9) | 7.2 (5.4 to 9.6) |
| Nausea | 2.5 (0.9 to 7.2) | 4.6 (2.0 to 10.4) | 6.0 (3.5 to 10.2) | 5.3 (3.5 to 8.0) | 5.6 (4.0 to 7.7) |
| Vomiting | 0.8 (0.1 to 4.6) | 0.0 (0.0 to 3.4) | 1.0 (0.3 to 3.6) | 0.8 (0.3 to 2.2) | 0.8 (0.4 to 2.0) |
| Fatigue | 20.0 (13.8 to 28.0) | 15.6 (10.0 to 23.6) | 16.5 (12.0 to 22.3) | 19.7 (16.1 to 23.9) | 18.6 (15.7 to 21.9) |
| Fever | 1.8 (0.5 to 6.3) | 0.0 (0.0 to 3.8) | 0.5 (0.1 to 3.0) | 1.1 (0.4 to 2.8) | 0.9 (0.4 to 2.1) |
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Pain | 55.6 (46.9 to 64.1) | 4.8 (2.1 to 10.7) | 8.5 (5.3 to 13.3) | 31.9 (27.5 to 36.7) | 24.3 (21.0 to 27.9) |
| Tenderness | 81.0 (73.2 to 86.9) | 9.5 (5.3 to 16.6) | 14.7 (10.3 to 20.4) | 47.3 (42.5 to 52.3) | 36.7 (32.9 to 40.7) |
| Erythema/Redness MGS | 16.3 (10.8 to 23.8) | 0.0 (0.0 to 3.5) | 1.6 (0.5 to 4.6) | 7.4 (5.2 to 10.5) | 5.5 (3.9 to 7.7) |
| Swelling MGS | 13.8 (8.8 to 21.0) | 0.0 (0.0 to 3.5) | 0.5 (0.1 to 2.9) | 5.4 (3.6 to 8.1) | 3.8 (2.5 to 5.7) |
| Induration/Hardening MGS | 12.1 (7.5 to 19.0) | 0.0 (0.0 to 3.5) | 0.0 (0.0 to 2.0) | 5.4 (3.5 to 8.1) | 3.6 (2.4 to 5.5) |
| Headache | 20.3 (14.2 to 28.3) | 10.6 (6.0 to 18.0) | 12.6 (8.6 to 18.1) | 15.5 (12.2 to 19.4) | 14.5 (11.9 to 17.6) |
| Muscle pain | 25.8 (18.9 to 34.2) | 3.8 (1.5 to 9.5) | 3.7 (1.8 to 7.4) | 14.1 (11.0 to 17.9) | 10.7 (8.4 to 13.5) |
| Joint pain | 4.9 (2.3 to 10.2) | 2.9 (1.0 to 8.1) | 1.6 (0.5 to 4.6) | 4.6 (3.0 to 7.2) | 3.6 (2.4 to 5.5) |
| Nausea | 4.9 (2.3 to 10.2) | 1.9 (0.5 to 6.7) | 5.8 (3.2 to 10.0) | 3.6 (2.2 to 6.0) | 4.3 (2.9 to 6.3) |
| Vomiting | 0.0 (0.0 to 3.0) | 1.0 (0.2 to 5.2) | 0.0 (0.0 to 2.0) | 1.3 (0.6 to 3.0) | 0.9 (0.4 to 2.0) |
| Fatigue | 13.8 (8.8 to 21.0) | 8.7 (4.6 to 15.6) | 12.1 (8.2 to 17.5) | 11.9 (9.0 to 15.5) | 12.0 (9.6 to 14.9) |
| Fever | 2.5 (0.9 to 7.2) | 0.0 (0.0 to 3.8) | 0.0 (0.0 to 2.1) | 0.8 (0.3 to 2.4) | 0.5 (0.2 to 1.6) |
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Pain | 57.5 (48.6 to 66.0) | 60.0 (50.4 to 68.9) | 5.6 (3.1 to 10.1) | 59.2 (54.1 to 64.1) | 41.7 (37.6 to 45.9) |
| Tenderness | 73.6 (65.1 to 80.6) | 82.1 (73.7 to 88.2) | 13.0 (8.8 to 18.7) | 78.2 (73.7 to 82.1) | 57.0 (52.8 to 61.1) |
| Erythema/Redness MGS | 11.7 (7.1 to 18.6) | 7.5 (3.9 to 14.2) | 1.1 (0.3 to 4.0) | 9.6 (7.0 to 13.1) | 6.8 (5.0 to 9.3) |
| Swelling MGS | 8.4 (4.6 to 14.8) | 11.3 (6.6 to 18.8) | 0.6 (0.1 to 3.1) | 9.1 (6.5 to 12.5) | 6.3 (4.5 to 8.7) |
| Induration/Hardening MGS | 8.4 (4.6 to 14.8) | 6.6 (3.2 to 13.0) | 0.6 (0.1 to 3.1) | 8.2 (5.8 to 11.5) | 5.7 (4.1 to 8.0) |
| Headache | 15.4 (10.0 to 23.0) | 18.9 (12.6 to 27.4) | 9.0 (5.6 to 14.1) | 18.5 (14.8 to 22.8) | 15.4 (12.6 to 18.7) |
| Muscle pain | 27.1 (19.9 to 35.8) | 29.2 (21.4 to 38.5) | 7.3 (4.3 to 12.2) | 28.3 (23.9 to 33.1) | 21.4 (18.2 to 25.1) |
| Joint pain | 8.5 (4.7 to 15.0) | 2.8 (1.0 to 8.0) | 3.4 (1.6 to 7.2) | 5.0 (3.2 to 7.7) | 4.4 (3.0 to 6.5) |
| Nausea | 1.7 (0.5 to 6.0) | 2.9 (1.0 to 8.1) | 2.3 (0.9 to 5.7) | 3.0 (1.7 to 5.4) | 2.8 (1.7 to 4.5) |
| Vomiting | 0.9 (0.2 to 4.7) | 1.9 (0.5 to 6.7) | 0.0 (0.0 to 2.1) | 1.1 (0.4 to 2.8) | 0.7 (0.3 to 1.9) |
| Fatigue | 17.9 (12.0 to 25.9) | 16.0 (10.3 to 24.2) | 11.8 (7.8 to 17.4) | 17.1 (13.6 to 21.3) | 15.4 (12.6 to 18.7) |
| Fever | 0.0 (0.0 to 3.3) | 1.0 (0.2 to 5.4) | 0.6 (0.1 to 3.2) | 0.9 (0.3 to 2.5) | 0.8 (0.3 to 2.0) |
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Pain | 80.5 (74.3 to 85.5) | 77.0 (70.5 to 82.5) | 16.8 (12.4 to 22.5) | 77.0 (72.7 to 80.8) | 57.0 (53.0 to 60.8) |
| Tenderness | 92.6 (88.0 to 95.6) | 92.5 (87.8 to 95.5) | 28.4 (22.7 to 34.8) | 90.6 (87.5 to 93.1) | 69.9 (66.2 to 73.4) |
| Erythema/ Redness MGS | 26.8 (21.0 to 33.6) | 18.7 (13.8 to 24.9) | 3.4 (1.6 to 6.8) | 21.8 (18.1 to 26.0) | 15.7 (13.0 to 18.7) |
| Swelling MGS | 20.5 (15.4 to 26.8) | 16.6 (11.9 to 22.6) | 1.4 (0.5 to 4.2) | 18.0 (14.6 to 22.0) | 12.5 (10.1 to 15.3) |
| Induration/ Hardening MGS | 19.5 (14.5 to 25.7) | 14.4 (10.1 to 20.2) | 1.4 (0.5 to 4.2) | 16.5 (13.3 to 20.4) | 11.5 (9.2 to 14.3) |
| Headache | 38.4 (31.8 to 45.5) | 36.4 (29.8 to 43.5) | 28.8 (23.1 to 35.3) | 37.4 (32.9 to 42.1) | 34.6 (30.9 to 38.4) |
| Muscle pain | 45.8 (38.9 to 52.9) | 48.1 (41.1 to 55.3) | 17.8 (13.2 to 23.6) | 46.8 (42.0 to 51.6) | 37.1 (33.4 to 41.0) |
| Joint pain | 15.3 (10.8 to 21.1) | 9.6 (6.2 to 14.7) | 8.2 (5.2 to 12.7) | 13.2 (10.3 to 16.8) | 11.5 (9.2 to 14.3) |
| Nausea | 8.4 (5.2 to 13.2) | 11.2 (7.5 to 16.6) | 9.6 (6.3 to 14.4) | 9.6 (7.1 to 12.8) | 9.6 (7.5 to 12.2) |
| Vomiting | 3.2 (1.5 to 6.7) | 3.2 (1.5 to 6.8) | 1.0 (0.3 to 3.4) | 2.9 (1.7 to 5.0) | 2.2 (1.3 to 3.7) |
| Fatigue | 33.2 (26.9 to 40.1) | 29.9 (23.8 to 36.9) | 28.4 (22.7 to 34.8) | 31.4 (27.1 to 36.0) | 30.4 (26.9 to 34.1) |
| Fever | 3.2 (1.5 to 6.7) | 1.6 (0.5 to 4.6) | 1.0 (0.3 to 3.4) | 2.4 (1.3 to 4.4) | 1.9 (1.1 to 3.3) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay at Day 208 was presented in this outcome measure.
| Titers | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| ST1 | 331.4 (273.5 to 401.5) | 197.3 (156.2 to 249.3) | 23.8 (21.6 to 26.2) |
| ST2 | 653.9 (557.9 to 766.3) | 460.3 (370.6 to 571.8) | 21.9 (20.2 to 23.7) |
| ST3 | 583.2 (494.4 to 688.0) | 436.2 (344.8 to 551.8) | 21.9 (20.2 to 23.9) |
| ST4 | 420.6 (353.2 to 500.9) | 245.8 (196.1 to 308.2) | 23.5 (21.3 to 25.9) |
| ST5 | 442.3 (374.2 to 522.7) | 239.4 (190.5 to 301.0) | 22.4 (20.6 to 24.4) |
| ST6 | 428.5 (358.8 to 511.8) | 222.0 (177.4 to 277.8) | 24.3 (22.2 to 26.7) |
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Pain | 53.7 (44.9 to 62.4) | 51.9 (42.5 to 61.0) | 6.0 (3.1 to 11.4) | 53.6 (47.9 to 59.3) | 38.7 (34.2 to 43.4) |
| Tenderness | 74.6 (66.2 to 81.5) | 76.4 (67.6 to 83.3) | 14.9 (9.9 to 21.9) | 75.7 (70.5 to 80.2) | 56.7 (52.0 to 61.3) |
| Erythema/Redness MGS | 7.6 (4.0 to 13.8) | 5.5 (2.5 to 11.5) | 2.2 (0.8 to 6.3) | 7.9 (5.3 to 11.6) | 6.1 (4.2 to 8.8) |
| Swelling MGS | 8.4 (4.6 to 14.8) | 6.5 (3.2 to 12.8) | 1.5 (0.4 to 5.2) | 8.7 (5.9 to 12.5) | 6.4 (4.4 to 9.1) |
| Induration/Hardening MGS | 5.0 (2.3 to 10.4) | 4.6 (2.0 to 10.4) | 1.5 (0.4 to 5.2) | 6.2 (3.9 to 9.6) | 4.7 (3.1 to 7.1) |
| Headache | 18.8 (12.8 to 26.8) | 11.9 (7.1 to 19.3) | 13.2 (8.5 to 20.0) | 15.3 (11.6 to 19.9) | 14.6 (11.6 to 18.3) |
| Muscle pain | 21.8 (15.4 to 30.1) | 33.3 (25.2 to 42.7) | 8.9 (5.2 to 14.9) | 28.9 (24.0 to 34.3) | 22.5 (18.8 to 26.7) |
| Joint pain | 5.9 (2.9 to 11.7) | 0.9 (0.2 to 5.1) | 1.5 (0.4 to 5.2) | 3.1 (1.7 to 5.9) | 2.6 (1.5 to 4.6) |
| Nausea | 5.1 (2.4 to 10.7) | 2.8 (1.0 to 7.9) | 1.5 (0.4 to 5.2) | 5.6 (3.5 to 8.9) | 4.3 (2.7 to 6.6) |
| Vomiting | 0.8 (0.1 to 4.6) | 0.9 (0.2 to 5.1) | 0.0 (0.0 to 2.8) | 1.0 (0.4 to 3.0) | 0.7 (0.2 to 2.1) |
| Fatigue | 13.6 (8.5 to 20.9) | 13.9 (8.6 to 21.7) | 7.4 (4.1 to 13.1) | 14.6 (11.0 to 19.1) | 12.3 (9.5 to 15.8) |
| Fever | 0.9 (0.2 to 5.0) | 0.0 (0.0 to 3.5) | 0.8 (0.1 to 4.2) | 0.4 (0.1 to 2.1) | 0.5 (0.1 to 1.8) |
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Pain | 62.4 (53.7 to 70.4) | 52.7 (43.5 to 61.7) | 6.7 (3.4 to 12.7) | 57.1 (51.1 to 62.9) | 41.6 (36.8 to 46.6) |
| Tenderness | 76.8 (68.7 to 83.3) | 74.1 (65.3 to 81.3) | 11.7 (7.1 to 18.6) | 76.5 (71.1 to 81.2) | 56.4 (51.5 to 61.3) |
| Erythema/Redness MGS | 17.6 (11.9 to 25.2) | 7.1 (3.7 to 13.5) | 1.7 (0.5 to 5.9) | 12.7 (9.2 to 17.2) | 9.3 (6.8 to 12.6) |
| Swelling MGS | 18.5 (12.7 to 26.3) | 7.1 (3.7 to 13.5) | 1.7 (0.5 to 5.9) | 14.2 (10.5 to 18.9) | 10.4 (7.7 to 13.8) |
| Induration/Hardening MGS | 12.1 (7.5 to 19.0) | 10.7 (6.2 to 17.8) | 2.5 (0.9 to 7.2) | 12.4 (8.9 to 16.8) | 9.3 (6.8 to 12.6) |
| Headache | 17.1 (11.4 to 24.7) | 15.3 (9.8 to 23.2) | 14.2 (9.0 to 21.5) | 17.7 (13.6 to 22.8) | 16.6 (13.2 to 20.7) |
| Muscle pain | 28.5 (21.2 to 37.0) | 30.6 (22.8 to 39.7) | 5.8 (2.9 to 11.6) | 30.2 (25.0 to 36.0) | 22.6 (18.7 to 27.0) |
| Joint pain | 8.9 (5.1 to 15.3) | 3.6 (1.4 to 8.9) | 3.3 (1.3 to 8.3) | 7.5 (4.9 to 11.4) | 6.2 (4.2 to 9.1) |
| Nausea | 3.3 (1.3 to 8.1) | 6.3 (3.1 to 12.3) | 4.1 (1.8 to 9.3) | 4.9 (2.9 to 8.2) | 4.7 (3.0 to 7.2) |
| Vomiting | 0.8 (0.1 to 4.5) | 0.9 (0.2 to 4.9) | 0.0 (0.0 to 3.1) | 1.1 (0.4 to 3.3) | 0.8 (0.3 to 2.3) |
| Fatigue | 19.5 (13.5 to 27.4) | 21.4 (14.8 to 29.9) | 6.7 (3.4 to 12.6) | 20.3 (15.9 to 25.5) | 16.1 (12.7 to 20.1) |
| Fever | 3.3 (1.3 to 8.2) | 1.8 (0.5 to 6.3) | 2.5 (0.9 to 7.1) | 2.3 (1.0 to 4.9) | 2.3 (1.2 to 4.4) |
Participants or their legal guardians were required to record any solicited local and systemic AEs in the electronic diary. Solicited symptoms were pre-defined symptoms which were collected via an electronic diary. Solicited local AEs included pain, tenderness, erythema/redness MGS, swelling MGS and induration/hardening MGS. Solicited systemic AEs included headache, muscle pain, joint pain, nausea, vomiting, fatigue and fever.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Pain | 54.4 (45.7 to 62.9) | 52.7 (43.5 to 61.8) | 6.4 (3.1 to 12.6) | 52.7 (46.4 to 58.8) | 38.3 (33.4 to 43.5) |
| Tenderness | 77.8 (69.8 to 84.2) | 81.3 (73.0 to 87.4) | 13.6 (8.4 to 21.3) | 77.8 (72.2 to 82.5) | 58.1 (52.9 to 63.1) |
| Erythema/Redness MGS | 16.9 (11.4 to 24.5) | 10.1 (5.7 to 17.2) | 1.8 (0.5 to 6.4) | 13.6 (9.8 to 18.5) | 9.9 (7.2 to 13.5) |
| Swelling MGS | 20.2 (14.0 to 28.1) | 11.0 (6.4 to 18.3) | 2.7 (0.9 to 7.7) | 15.6 (11.6 to 20.7) | 11.6 (8.7 to 15.4) |
| Induration/Hardening MGS | 13.7 (8.7 to 20.9) | 11.0 (6.4 to 18.3) | 1.8 (0.5 to 6.4) | 11.9 (8.4 to 16.6) | 8.8 (6.3 to 12.2) |
| Headache | 25.2 (18.4 to 33.5) | 14.5 (9.2 to 22.3) | 19.6 (13.3 to 28.0) | 19.8 (15.2 to 25.2) | 19.7 (15.9 to 24.2) |
| Muscle pain | 22.6 (16.1 to 30.7) | 22.7 (15.9 to 31.4) | 6.3 (3.1 to 12.3) | 22.5 (17.7 to 28.2) | 17.4 (13.8 to 21.7) |
| Joint pain | 6.5 (3.3 to 12.3) | 2.8 (0.9 to 7.8) | 1.8 (0.5 to 6.3) | 4.5 (2.6 to 8.0) | 3.7 (2.2 to 6.2) |
| Nausea | 3.3 (1.3 to 8.1) | 4.6 (2.0 to 10.3) | 3.6 (1.4 to 8.9) | 4.1 (2.3 to 7.4) | 4.0 (2.4 to 6.5) |
| Vomiting | 0.0 (0.0 to 3.0) | 0.9 (0.2 to 5.0) | 0.9 (0.2 to 4.9) | 0.4 (0.1 to 2.3) | 0.6 (0.2 to 2.0) |
| Fatigue | 11.4 (6.9 to 18.2) | 15.6 (10.0 to 23.6) | 7.1 (3.7 to 13.5) | 12.8 (9.2 to 17.6) | 11.0 (8.2 to 14.7) |
| Fever | 0.8 (0.1 to 4.6) | 0.0 (0.0 to 3.5) | 1.9 (0.5 to 6.7) | 0.4 (0.1 to 2.4) | 0.9 (0.3 to 2.6) |
A SAE was any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) | 0.0 (0.0 to 2.9) | 3.6 (1.4 to 8.8) | 6.8 (4.1 to 11.1) | 3.3 (2.0 to 5.5) | 4.5 (3.1 to 6.4) |
An AESI (serious or non-serious) was one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor were appropriate.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events of Special Interest (AESIs) | 0.8 (0.1 to 4.3) | 2.7 (0.9 to 7.6) | 0.5 (0.1 to 2.7) | 3.3 (2.0 to 5.5) | 2.4 (1.5 to 3.9) |
An AE was any untoward medical occurrence in a participant administered an investigational product, whether or not related to this treatment. Unsolicited AEs were defined as any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Percentage of Participants With Unsolicited AE | 29.1 (21.9 to 37.6) | 36.6 (28.3 to 45.8) | 35.0 (28.8 to 41.7) | 30.8 (26.6 to 35.4) | 32.2 (28.6 to 35.9) |
Percentage of participants with SAEs, AESIs, solicited and unsolicited AEs stratified by age group 5-11, 12-17 and 18-65 years were reported. SAE: any untoward medical occurrence that at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was another medically important condition. AESI: scientific and medical concern specific to the sponsor's product or program. Solicited AE: predefined reactions at injection site or systemic reactions after each vaccination. Unsolicited AEs: any solicited local or systemic AE if it had an onset date more than 6 days after vaccination or any other symptom or untoward medical event.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| 5-11 Years, SAEs | 0.0 (0.0 to 10.7) | 4.0 (0.7 to 19.5) | 3.9 (1.1 to 13.2) | 2.9 (1.0 to 8.1) | 3.2 (1.4 to 7.3) |
| 5-11 Years, AESIs | 0.0 (0.0 to 10.7) | 8.0 (2.2 to 25.0) | 0.0 (0.0 to 7.0) | 2.9 (1.0 to 8.1) | 1.9 (0.7 to 5.5) |
| 5-11 Years, Solicited AEs | 93.8 (79.9 to 98.3) | 96.0 (80.5 to 99.3) | 76.5 (63.2 to 86.0) | 94.2 (88.0 to 97.3) | 88.4 (82.4 to 92.5) |
| 5-11 Years, Unsolicited AEs | 15.6 (6.9 to 31.8) | 32.0 (17.2 to 51.6) | 29.4 (18.7 to 43.0) | 19.2 (12.8 to 27.8) | 22.6 (16.7 to 29.8) |
| 12-17 Years, SAEs | 0.0 (0.0 to 12.1) | 0.0 (0.0 to 13.8) | 6.0 (2.1 to 16.2) | 3.0 (1.0 to 8.5) | 4.0 (1.8 to 8.5) |
| 12-17 Years, AESIs | 0.0 (0.0 to 12.1) | 0.0 (0.0 to 13.8) | 2.0 (0.4 to 10.5) | 2.0 (0.6 to 7.0) | 2.0 (0.7 to 5.7) |
| 12-17 Years, Solicited AEs | 96.4 (82.3 to 99.4) | 100 (86.2 to 100) | 64.0 (50.1 to 75.9) | 97.0 (91.5 to 99.0) | 86.0 (79.5 to 90.7) |
| 12-17 Years, Unsolicited AEs | 35.7 (20.7 to 54.2) | 20.8 (9.2 to 40.5) | 30.0 (19.1 to 43.8) | 25.0 (17.5 to 34.3) | 26.7 (20.2 to 34.3) |
| 18-65 Years, SAEs | 0.0 (0.0 to 5.4) | 4.8 (1.6 to 13.1) | 8.6 (4.6 to 15.5) | 3.7 (1.9 to 7.2) | 5.3 (3.3 to 8.3) |
| 18-65 Years, AESIs | 1.5 (0.3 to 8.0) | 1.6 (0.3 to 8.5) | 0.0 (0.0 to 3.5) | 4.2 (2.2 to 7.8) | 2.8 (1.5 to 5.3) |
| 18-65 Years, Solicited AEs | 98.5 (92.0 to 99.7) | 100 (94.3 to 100) | 68.6 (59.2 to 76.7) | 96.7 (93.4 to 98.4) | 87.5 (83.4 to 90.7) |
| 18-65 Years, Unsolicited AEs | 32.8 (22.8 to 44.7) | 44.4 (32.8 to 56.7) | 40.0 (31.1 to 49.6) | 39.1 (32.8 to 45.7) | 39.4 (34.2 to 44.8) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay were evaluated.
| Titers | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| ST1: Baseline | 21.2 (20.3 to 22.1) | 20.3 (19.9 to 20.7) | 21.9 (20.7 to 23.2) |
| ST1: Day 85 | 116.5 (96.4 to 140.8) | 20.8 (20.1 to 21.5) | 21.8 (20.5 to 23.3) |
| ST1: Day 180 | 38.2 (33.6 to 43.4) | 21.4 (20.5 to 22.3) | 22.0 (20.8 to 23.2) |
| ST1: Day 365 | 40.8 (35.3 to 47.1) | 30.2 (27.1 to 33.6) | 21.3 (20.3 to 22.4) |
| ST1: Month 18 | 27.3 (24.2 to 30.7) | 22.7 (21.3 to 24.2) | 21.2 (20.2 to 22.3) |
| ST2: Baseline | 20.8 (20.0 to 21.6) | 20.0 (20.0 to 20.0) | 21.3 (20.4 to 22.3) |
| ST2: Day 85 | 262.8 (217.6 to 317.3) | 21.8 (20.6 to 23.1) | 21.0 (19.9 to 22.1) |
| ST2: Day 180 | 70.4 (60.4 to 82.1) | 21.9 (20.8 to 23.1) | 21.1 (20.3 to 22.1) |
| ST2: Day 365 | 67.8 (58.2 to 78.9) | 54.1 (46.8 to 62.7) | 20.9 (20.1 to 21.7) |
| ST2: Month 18 | 35.4 (31.1 to 40.2) | 30.3 (27.2 to 33.8) | 20.3 (19.9 to 20.9) |
| ST3: Baseline | 20.6 (20.0 to 21.3) | 20.3 (19.9 to 20.7) | 20.9 (20.2 to 21.7) |
| ST3: Day 85 | 249.8 (205.1 to 304.2) | 22.7 (21.5 to 24.1) | 20.9 (19.8 to 22.2) |
| ST3: Day 180 | 65.4 (55.8 to 76.6) | 22.3 (21.2 to 23.6) | 21.1 (20.4 to 21.8) |
| ST3: Day 365 | 63.1 (53.8 to 74.0) | 58.1 (49.8 to 67.8) | 20.6 (20.0 to 21.1) |
| ST3: Month 18 | 34.3 (29.8 to 39.4) | 33.8 (30.1 to 37.9) | 20.1 (19.9 to 20.3) |
| ST4: Baseline | 20.8 (20.0 to 21.6) | 20.4 (20.0 to 20.9) | 21.7 (20.6 to 22.8) |
| ST4: Day 85 | 147.4 (122.6 to 177.3) | 21.7 (20.7 to 22.7) | 21.6 (20.3 to 23.0) |
| ST4: Day 180 | 47.5 (41.7 to 54.1) | 22.1 (21.1 to 23.2) | 22.4 (21.1 to 23.7) |
| ST4: Day 365 | 52.6 (45.5 to 60.8) | 37.2 (33.1 to 41.9) | 20.9 (20.0 to 21.8) |
| ST4: Month 18 | 32.3 (28.5 to 36.7) | 25.8 (23.7 to 28.1) | 21.0 (20.1 to 22.0) |
| ST5: Baseline | 20.6 (19.8 to 21.4) | 20.2 (19.9 to 20.6) | 20.7 (20.1 to 21.4) |
| ST5: Day 85 | 164.2 (135.7 to 198.8) | 21.2 (20.3 to 22.0) | 20.9 (19.9 to 22.1) |
| ST5: Day 180 | 52.3 (45.5 to 60.1) | 21.7 (20.7 to 22.7) | 20.8 (20.2 to 21.5) |
| ST5: Day 365 | 54.6 (47.0 to 63.5) | 38.4 (33.9 to 43.5) | 20.4 (19.9 to 20.9) |
| ST5: Month 18 | 29.3 (25.9 to 33.1) | 24.9 (23.0 to 27.0) | 20.2 (19.9 to 20.5) |
| ST6: Baseline | 22.5 (20.9 to 24.2) | 21.3 (20.4 to 22.2) | 22.1 (21.0 to 23.2) |
| ST6: Day 85 | 143.7 (119.2 to 173.1) | 22.5 (21.2 to 23.9) | 22.3 (20.9 to 23.9) |
| ST6: Day 180 | 49.3 (42.8 to 56.8) | 23.2 (21.9 to 24.7) | 22.5 (21.4 to 23.7) |
| ST6: Day 365 | 57.2 (49.2 to 66.6) | 38.1 (33.8 to 42.9) | 21.9 (20.9 to 23.1) |
| ST6: Month 18 | 32.2 (28.1 to 36.9) | 25.7 (23.5 to 28.0) | 21.2 (20.4 to 22.1) |
Seroconversion for enzyme linked immunosorbent assay (ELISA) was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a greater than or equal to (\>=) 4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| ST1: Day 85 | 75.0 (67.9 to 80.9) | 2.6 (1.0 to 6.4) | 1.8 (0.6 to 5.1) |
| ST1: Day 180 | 40.4 (33.3 to 47.8) | 5.0 (2.5 to 9.5) | 2.9 (1.2 to 6.6) |
| ST1: Day 208 | 92.9 (88.1 to 95.9) | 83.5 (77.0 to 88.5) | 6.7 (3.8 to 11.5) |
| ST1: Day 365 | 43.2 (35.8 to 50.9) | 28.8 (22.3 to 36.4) | 0.6 (0.1 to 3.5) |
| ST1: Month 18 | 16.6 (11.6 to 23.2) | 9.7 (5.9 to 15.7) | 0.0 (0.0 to 2.4) |
| ST2: Day 85 | 89.9 (84.4 to 93.6) | 6.5 (3.5 to 11.5) | 0.6 (0.1 to 3.3) |
| ST2: Day 180 | 66.7 (59.3 to 73.3) | 7.5 (4.3 to 12.6) | 1.2 (0.3 to 4.1) |
| ST2: Day 208 | 97.6 (94.1 to 99.1) | 94.3 (89.5 to 97.0) | 2.4 (0.9 to 6.1) |
| ST2: Day 365 | 64.8 (57.2 to 71.7) | 59.0 (51.1 to 66.4) | 1.3 (0.3 to 4.5) |
| ST2: Month 18 | 36.3 (29.2 to 44.1) | 31.3 (24.2 to 39.2) | 0.0 (0.0 to 2.4) |
| ST3: Day 85 | 90.5 (85.1 to 94.1) | 11.0 (7.0 to 16.9) | 0.6 (0.1 to 3.3) |
| ST3: Day 180 | 63.7 (56.3 to 70.6) | 8.7 (5.3 to 14.1) | 4.1 (2.0 to 8.2) |
| ST3: Day 208 | 98.8 (95.8 to 99.7) | 91.8 (86.4 to 95.1) | 4.2 (2.1 to 8.5) |
| ST3: Day 365 | 63.0 (55.3 to 70.0) | 61.5 (53.7 to 68.8) | 0.6 (0.1 to 3.5) |
| ST3: Month 18 | 31.2 (24.5 to 38.8) | 40.3 (32.6 to 48.4) | 0.6 (0.1 to 3.5) |
| ST4: Day 85 | 83.9 (77.6 to 88.7) | 5.2 (2.6 to 9.9) | 2.4 (0.9 to 5.9) |
| ST4: Day 180 | 55.0 (47.5 to 62.2) | 8.1 (4.8 to 13.3) | 6.4 (3.6 to 11.1) |
| ST4: Day 208 | 95.9 (91.7 to 98.0) | 88.6 (82.7 to 92.7) | 6.7 (3.8 to 11.5) |
| ST4: Day 365 | 57.4 (49.7 to 64.8) | 42.9 (35.4 to 50.8) | 1.3 (0.3 to 4.5) |
| ST4: Month 18 | 31.2 (24.5 to 38.8) | 19.4 (13.8 to 26.7) | 1.3 (0.4 to 4.6) |
| ST5: Day 85 | 82.7 (76.3 to 87.7) | 4.5 (2.2 to 9.0) | 2.4 (0.9 to 5.9) |
| ST5: Day 180 | 57.9 (50.4 to 65.0) | 5.6 (3.0 to 10.3) | 4.1 (2.0 to 8.2) |
| ST5: Day 208 | 97.1 (93.3 to 98.7) | 86.7 (80.5 to 91.1) | 6.7 (3.8 to 11.5) |
| ST5: Day 365 | 57.4 (49.7 to 64.8) | 43.6 (36.1 to 51.4) | 1.3 (0.3 to 4.5) |
| ST5: Month 18 | 23.6 (17.6 to 30.8) | 17.4 (12.0 to 24.4) | 1.3 (0.4 to 4.6) |
| ST6: Day 85 | 79.9 (73.2 to 85.2) | 4.5 (2.2 to 9.0) | 2.4 (0.9 to 5.9) |
| ST6: Day 180 | 50.0 (42.6 to 57.4) | 8.7 (5.3 to 14.1) | 5.2 (2.8 to 9.6) |
| ST6: Day 208 | 95.3 (91.0 to 97.6) | 85.4 (79.1 to 90.1) | 8.5 (5.1 to 13.7) |
| ST6: Day 365 | 57.1 (49.4 to 64.4) | 41.7 (34.2 to 49.5) | 3.2 (1.4 to 7.2) |
| ST6: Month 18 | 22.2 (16.4 to 29.2) | 16.7 (11.5 to 23.6) | 2.6 (1.0 to 6.4) |
GMFR for IgG when compared to baseline against each OspA serotype ST1 to ST6, determined by IgG binding assay at Day 85 and Day 208 were evaluated.
| Fold rise | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| ST1: Day 85 | 5.5 (4.5 to 6.6) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| ST1: Day 208 | 15.5 (12.8 to 18.8) | 9.7 (7.7 to 12.3) | 1.1 (1.0 to 1.2) |
| ST2: Day 85 | 12.5 (10.4 to 15.2) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.0) |
| ST2: Day 208 | 31.4 (26.6 to 36.9) | 23.0 (18.5 to 28.6) | 1.0 (1.0 to 1.1) |
| ST3: Day 85 | 12.0 (9.8 to 14.6) | 1.1 (1.1 to 1.2) | 1.0 (1.0 to 1.0) |
| ST3: Day 208 | 28.1 (23.8 to 33.2) | 21.7 (17.1 to 27.4) | 1.0 (1.0 to 1.1) |
| ST4: Day 85 | 7.0 (5.8 to 8.4) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| ST4: Day 208 | 20.0 (16.8 to 23.9) | 12.0 (9.6 to 15.0) | 1.1 (1.0 to 1.2) |
| ST5: Day 85 | 7.9 (6.5 to 9.6) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) |
| ST5: Day 208 | 21.3 (17.9 to 25.2) | 11.8 (9.4 to 14.8) | 1.1 (1.0 to 1.2) |
| ST6: Day 85 | 6.4 (5.3 to 7.7) | 1.1 (1.0 to 1.1) | 1.0 (1.0 to 1.1) |
| ST6: Day 208 | 19.0 (15.9 to 22.8) | 10.4 (8.3 to 13.0) | 1.1 (1.0 to 1.2) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay stratified by age group (5-11, 12-17 and 18-65 years) were evaluated. Day 194 data was reported for adult participants only as pre-specified in protocol.
| Titers | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| 5-11 Years, ST1: Baseline | 21.8 (19.7 to 24.0) | 21.3 (19.4 to 23.4) | 22.9 (20.1 to 26.2) |
| 5-11 Years, ST1: Day 85 | 269.5 (219.8 to 330.5) | 22.2 (19.7 to 25.1) | 23.0 (18.6 to 28.6) |
| 5-11 Years, ST1: Day 180 | 57.6 (44.8 to 74.0) | 22.3 (19.6 to 25.3) | 21.4 (19.4 to 23.6) |
| 5-11 Years, ST1: Day 365 | 63.4 (46.7 to 86.1) | 44.3 (33.5 to 58.6) | 20.8 (19.2 to 22.5) |
| 5-11 Years, ST1: Month 18 | 30.8 (23.6 to 40.1) | 23.2 (20.0 to 26.9) | 20.8 (19.2 to 22.6) |
| 5-11 Years, ST2: Baseline | 20.6 (19.4 to 22.0) | 20.0 (20.0 to 20.0) | 22.9 (20.0 to 26.3) |
| 5-11 Years, ST2: Day 85 | 625.2 (482.4 to 810.3) | 23.1 (20.0 to 26.6) | 22.0 (18.1 to 26.7) |
| 5-11 Years, ST2: Day 180 | 151.0 (117.2 to 194.5) | 21.3 (19.5 to 23.3) | 20.8 (19.2 to 22.7) |
| 5-11 Years, ST2: Day 365 | 138.9 (107.7 to 179.2) | 98.0 (73.2 to 131.2) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST2: Month 18 | 48.7 (36.4 to 65.1) | 39.5 (30.5 to 51.0) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST3: Baseline | 20.8 (19.7 to 22.1) | 20.0 (20.0 to 20.0) | 22.2 (19.7 to 24.9) |
| 5-11 Years, ST3: Day 85 | 649.6 (494.7 to 853.1) | 24.4 (20.8 to 28.5) | 23.0 (18.1 to 29.3) |
| 5-11 Years, ST3: Day 180 | 135.9 (100.2 to 184.5) | 22.0 (20.0 to 24.3) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST3: Day 365 | 118.6 (85.0 to 165.5) | 120.6 (91.1 to 159.6) | 20.4 (19.6 to 21.4) |
| 5-11 Years, ST3: Month 18 | 50.0 (36.4 to 68.8) | 50.9 (39.6 to 65.6) | 20.5 (19.5 to 21.5) |
| 5-11 Years, ST4: Baseline | 20.5 (19.5 to 21.6) | 20.0 (20.0 to 20.0) | 22.1 (19.7 to 24.9) |
| 5-11 Years, ST4: Day 85 | 354.9 (275.2 to 457.7) | 22.5 (20.0 to 25.2) | 22.6 (18.4 to 27.8) |
| 5-11 Years, ST4: Day 180 | 84.7 (65.3 to 109.8) | 21.6 (19.8 to 23.6) | 21.3 (19.5 to 23.3) |
| 5-11 Years, ST4: Day 365 | 96.1 (71.8 to 128.4) | 58.0 (46.0 to 73.1) | 20.5 (19.5 to 21.4) |
| 5-11 Years, ST4: Month 18 | 42.9 (31.3 to 58.8) | 26.6 (22.5 to 31.3) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST5: Baseline | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) | 21.9 (19.7 to 24.2) |
| 5-11 Years, ST5: Day 85 | 441.2 (339.3 to 573.7) | 21.6 (19.7 to 23.6) | 22.8 (18.3 to 28.4) |
| 5-11 Years, ST5: Day 180 | 109.9 (84.1 to 143.6) | 21.5 (19.3 to 23.9) | 21.2 (19.5 to 22.9) |
| 5-11 Years, ST5: Day 365 | 116.6 (87.9 to 154.7) | 55.1 (41.6 to 73.0) | 20.8 (19.2 to 22.4) |
| 5-11 Years, ST5: Month 18 | 38.1 (28.6 to 50.8) | 28.1 (23.2 to 34.1) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST6: Baseline | 26.2 (20.6 to 33.4) | 20.9 (19.7 to 22.2) | 23.8 (20.7 to 27.3) |
| 5-11 Years, ST6: Day 85 | 380.4 (293.3 to 493.5) | 22.6 (20.1 to 25.4) | 24.2 (19.0 to 30.9) |
| 5-11 Years, ST6: Day 180 | 96.6 (71.4 to 130.6) | 24.1 (21.1 to 27.5) | 23.0 (20.3 to 26.0) |
| 5-11 Years, ST6: Day 365 | 113.1 (84.7 to 151.1) | 64.0 (50.3 to 81.4) | 22.0 (19.6 to 24.7) |
| 5-11 Years, ST6: Month 18 | 44.2 (31.1 to 62.8) | 28.8 (23.6 to 35.2) | 20.5 (19.5 to 21.6) |
| 12-17 Years, ST1: Baseline | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) | 21.0 (19.6 to 22.6) |
| 12-17 Years, ST1: Day 85 | 198.4 (136.9 to 287.7) | 20.8 (19.7 to 21.9) | 20.6 (19.4 to 21.9) |
| 12-17 Years, ST1: Day 180 | 48.3 (36.8 to 63.5) | 22.6 (20.3 to 25.2) | 21.9 (20.0 to 24.1) |
| 12-17 Years, ST1: Day 365 | 43.9 (31.8 to 60.5) | 36.5 (28.7 to 46.4) | 20.6 (19.4 to 22.0) |
| 12-17 Years, ST1: Month 18 | 31.0 (22.8 to 42.1) | 24.6 (20.9 to 28.9) | 20.6 (19.4 to 22.0) |
| 12-17 Years, ST2: Baseline | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST2: Day 85 | 414.3 (284.2 to 604.1) | 23.7 (19.9 to 28.2) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST2: Day 180 | 102.3 (74.0 to 141.4) | 24.6 (21.0 to 28.9) | 21.2 (19.5 to 22.9) |
| 12-17 Years, ST2: Day 365 | 68.6 (47.9 to 98.2) | 72.8 (53.6 to 98.8) | 20.7 (19.3 to 22.2) |
| 12-17 Years, ST2: Month 18 | 39.8 (28.2 to 56.2) | 39.3 (30.4 to 50.9) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST3: Baseline | 20.0 (20.0 to 20.0) | 20.5 (19.5 to 21.5) | 20.4 (19.6 to 21.2) |
| 12-17 Years, ST3: Day 85 | 426.3 (288.0 to 631.2) | 24.8 (21.5 to 28.6) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST3: Day 180 | 104.5 (75.8 to 143.9) | 25.1 (21.5 to 29.4) | 21.5 (19.8 to 23.5) |
| 12-17 Years, ST3: Day 365 | 73.2 (50.8 to 105.5) | 86.1 (63.4 to 116.8) | 20.7 (19.3 to 22.3) |
| 12-17 Years, ST3: Month 18 | 41.5 (28.3 to 61.0) | 44.8 (34.4 to 58.3) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST4: Baseline | 20.0 (20.0 to 20.0) | 21.8 (20.0 to 23.7) | 21.4 (19.8 to 23.1) |
| 12-17 Years, ST4: Day 85 | 256.6 (181.0 to 363.7) | 23.7 (20.7 to 27.0) | 21.1 (19.5 to 22.8) |
| 12-17 Years, ST4: Day 180 | 68.0 (52.3 to 88.5) | 24.1 (21.3 to 27.2) | 22.2 (20.0 to 24.7) |
| 12-17 Years, ST4: Day 365 | 58.6 (42.6 to 80.7) | 52.4 (40.0 to 68.6) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST4: Month 18 | 38.0 (27.7 to 52.2) | 33.6 (26.8 to 42.0) | 21.0 (19.6 to 22.5) |
| 12-17 Years, ST5: Baseline | 20.0 (20.0 to 20.0) | 21.0 (19.6 to 22.6) | 21.0 (19.6 to 22.5) |
| 12-17 Years, ST5: Day 85 | 273.7 (190.5 to 393.4) | 22.8 (20.1 to 25.9) | 21.0 (19.6 to 22.5) |
| 12-17 Years, ST5: Day 180 | 71.7 (53.2 to 96.7) | 24.2 (21.1 to 27.7) | 20.6 (19.4 to 21.8) |
| 12-17 Years, ST5: Day 365 | 60.0 (42.6 to 84.4) | 56.4 (43.1 to 73.8) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST5: Month 18 | 35.8 (25.5 to 50.1) | 29.5 (23.9 to 36.4) | 20.6 (19.4 to 21.9) |
| 12-17 Years, ST6: Baseline | 20.9 (19.6 to 22.4) | 23.6 (20.4 to 27.2) | 23.2 (20.4 to 26.4) |
| 12-17 Years, ST6: Day 85 | 229.4 (157.8 to 333.4) | 26.3 (21.6 to 31.8) | 22.8 (20.1 to 26.0) |
| 12-17 Years, ST6: Day 180 | 66.2 (49.0 to 89.4) | 27.3 (23.0 to 32.5) | 23.8 (20.9 to 27.0) |
| 12-17 Years, ST6: Day 365 | 66.5 (47.4 to 93.2) | 51.2 (39.4 to 66.5) | 21.7 (19.7 to 23.8) |
| 12-17 Years, ST6: Month 18 | 37.5 (26.8 to 52.3) | 31.9 (25.2 to 40.5) | 22.3 (20.1 to 24.9) |
| 18-65 Years, ST1: Baseline | 21.4 (20.0 to 23.0) | 20.0 (20.0 to 20.0) | 21.9 (20.1 to 23.8) |
| 18-65 Years, ST1: Day 85 | 66.4 (51.8 to 85.1) | 20.3 (19.7 to 20.8) | 21.9 (20.2 to 23.7) |
| 18-65 Years, ST1: Day 180 | 29.4 (25.0 to 34.6) | 20.4 (19.8 to 21.1) | 22.3 (20.5 to 24.2) |
| 18-65 Years, ST1: Day 194 | 360.8 (238.2 to 546.6) | 91.6 (60.0 to 139.6) | 20.8 (19.7 to 22.0) |
| 18-65 Years, ST1: Day 365 | 33.4 (27.8 to 40.0) | 23.1 (21.0 to 25.4) | 21.8 (20.1 to 23.6) |
| 18-65 Years, ST1: Month 18 | 24.6 (21.2 to 28.4) | 21.6 (20.2 to 23.2) | 21.6 (19.9 to 23.4) |
| 18-65 Years, ST2: Baseline | 21.2 (19.8 to 22.7) | 20.0 (20.0 to 20.0) | 21.3 (20.0 to 22.7) |
| 18-65 Years, ST2: Day 85 | 152.4 (120.0 to 193.6) | 20.4 (19.8 to 21.0) | 21.0 (19.9 to 22.1) |
| 18-65 Years, ST2: Day 180 | 44.5 (37.3 to 53.1) | 21.0 (19.8 to 22.1) | 21.3 (20.0 to 22.6) |
| 18-65 Years, ST2: Day 194 | 691.5 (519.0 to 921.3) | 216.7 (143.9 to 326.2) | 21.0 (19.5 to 22.7) |
| 18-65 Years, ST2: Day 365 | 50.9 (42.3 to 61.4) | 35.9 (30.6 to 42.3) | 21.3 (20.0 to 22.8) |
| 18-65 Years, ST2: Month 18 | 29.5 (25.6 to 34.0) | 23.5 (21.4 to 25.9) | 20.6 (19.7 to 21.6) |
| 18-65 Years, ST3: Baseline | 20.8 (19.7 to 22.0) | 20.3 (19.7 to 20.9) | 20.7 (19.9 to 21.5) |
| 18-65 Years, ST3: Day 85 | 135.2 (106.4 to 171.9) | 21.2 (20.1 to 22.3) | 20.5 (19.8 to 21.3) |
| 18-65 Years, ST3: Day 180 | 40.2 (33.8 to 47.9) | 21.2 (20.0 to 22.6) | 21.3 (20.3 to 22.4) |
| 18-65 Years, ST3: Day 194 | 589.2 (428.7 to 809.9) | 196.6 (129.9 to 297.6) | 21.2 (19.8 to 22.8) |
| 18-65 Years, ST3: Day 365 | 46.6 (38.6 to 56.3) | 34.6 (29.4 to 40.6) | 20.5 (19.8 to 21.3) |
| 18-65 Years, ST3: Month 18 | 27.0 (23.5 to 31.1) | 24.2 (22.0 to 26.6) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST4: Baseline | 21.3 (19.9 to 22.8) | 20.0 (20.0 to 20.0) | 21.6 (20.0 to 23.4) |
| 18-65 Years, ST4: Day 85 | 81.8 (65.3 to 102.6) | 20.5 (19.8 to 21.1) | 21.5 (20.0 to 23.2) |
| 18-65 Years, ST4: Day 180 | 32.5 (28.1 to 37.6) | 21.4 (20.3 to 22.7) | 22.9 (20.9 to 25.0) |
| 18-65 Years, ST4: Day 194 | 434.4 (306.2 to 616.3) | 112.4 (75.7 to 166.9) | 22.5 (19.7 to 25.7) |
| 18-65 Years, ST4: Day 365 | 39.9 (33.5 to 47.6) | 25.9 (23.1 to 29.0) | 21.4 (19.9 to 23.2) |
| 18-65 Years, ST4: Month 18 | 26.8 (23.4 to 30.8) | 22.3 (20.5 to 24.3) | 21.5 (19.9 to 23.3) |
| 18-65 Years, ST5: Baseline | 21.1 (19.7 to 22.6) | 20.0 (20.0 to 20.0) | 20.2 (19.8 to 20.6) |
| 18-65 Years, ST5: Day 85 | 88.6 (70.4 to 111.4) | 20.2 (19.8 to 20.6) | 20.2 (19.8 to 20.7) |
| 18-65 Years, ST5: Day 180 | 34.1 (29.5 to 39.5) | 20.6 (19.8 to 21.5) | 20.8 (20.0 to 21.7) |
| 18-65 Years, ST5: Day 194 | 450.5 (328.9 to 617.2) | 117.1 (78.1 to 175.7) | 21.1 (19.9 to 22.4) |
| 18-65 Years, ST5: Day 365 | 39.2 (32.9 to 46.7) | 27.2 (24.0 to 30.7) | 20.4 (19.8 to 21.1) |
| 18-65 Years, ST5: Month 18 | 24.2 (21.4 to 27.4) | 21.7 (20.3 to 23.1) | 20.2 (19.8 to 20.5) |
| 18-65 Years, ST6: Baseline | 21.7 (20.0 to 23.6) | 20.5 (19.8 to 21.1) | 21.0 (20.0 to 21.9) |
| 18-65 Years, ST6: Day 85 | 79.3 (63.5 to 98.9) | 20.8 (19.9 to 21.9) | 21.4 (20.3 to 22.6) |
| 18-65 Years, ST6: Day 180 | 33.4 (28.7 to 38.9) | 21.1 (20.0 to 22.3) | 21.8 (20.5 to 23.1) |
| 18-65 Years, ST6: Day 194 | 405.5 (289.5 to 568.1) | 104.8 (70.1 to 156.5) | 21.7 (20.0 to 23.5) |
| 18-65 Years, ST6: Day 365 | 41.4 (34.5 to 49.7) | 26.2 (23.4 to 29.2) | 22.0 (20.5 to 23.6) |
| 18-65 Years, ST6: Month 18 | 26.5 (23.0 to 30.6) | 21.8 (20.3 to 23.3) | 21.1 (20.0 to 22.3) |
Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA. Day 194 data was reported for adult participants only as pre-specified in protocol.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| 5-11 Years, ST1: Day 85 | 97.4 (86.5 to 99.5) | 2.9 (0.5 to 14.9) | 2.6 (0.5 to 13.5) |
| 5-11 Years, ST1: Day 180 | 67.6 (51.5 to 80.4) | 2.6 (0.5 to 13.5) | 0.0 (0.0 to 9.0) |
| 5-11 Years, ST1: Day 208 | 97.4 (86.5 to 99.5) | 97.3 (86.2 to 99.5) | 2.6 (0.5 to 13.2) |
| 5-11 Years, ST1: Day 365 | 65.7 (49.2 to 79.2) | 51.4 (35.9 to 66.6) | 0.0 (0.0 to 9.9) |
| 5-11 Years, ST1: Month 18 | 20.0 (10.0 to 35.9) | 8.8 (3.0 to 23.0) | 0.0 (0.0 to 9.4) |
| 5-11 Years, ST2: Day 85 | 97.4 (86.5 to 99.5) | 11.8 (4.7 to 26.6) | 2.6 (0.5 to 13.5) |
| 5-11 Years, ST2: Day 180 | 94.6 (82.3 to 98.5) | 5.3 (1.5 to 17.3) | 0.0 (0.0 to 9.0) |
| 5-11 Years, ST2: Day 208 | 97.4 (86.5 to 99.5) | 100 (90.6 to 100) | 2.6 (0.5 to 13.2) |
| 5-11 Years, ST2: Day 365 | 91.4 (77.6 to 97.0) | 83.8 (68.9 to 92.3) | 0.0 (0.0 to 9.9) |
| 5-11 Years, ST2: Month 18 | 57.1 (40.9 to 72.0) | 50.0 (34.1 to 65.9) | 0.0 (0.0 to 9.4) |
| 5-11 Years, ST3: Day 85 | 97.4 (86.5 to 99.5) | 17.6 (8.3 to 33.5) | 2.6 (0.5 to 13.5) |
| 5-11 Years, ST3: Day 180 | 89.2 (75.3 to 95.7) | 10.5 (4.2 to 24.1) | 0.0 (0.0 to 9.0) |
| 5-11 Years, ST3: Day 208 | 97.4 (86.5 to 99.5) | 100 (90.6 to 100) | 2.6 (0.5 to 13.2) |
| 5-11 Years, ST3: Day 365 | 80.0 (64.1 to 90.0) | 91.9 (78.7 to 97.2) | 0.0 (0.0 to 9.9) |
| 5-11 Years, ST3: Month 18 | 54.3 (38.2 to 69.5) | 70.6 (53.8 to 83.2) | 2.7 (0.5 to 13.8) |
| 5-11 Years, ST4: Day 85 | 97.4 (86.5 to 99.5) | 11.8 (4.7 to 26.6) | 5.3 (1.5 to 17.3) |
| 5-11 Years, ST4: Day 180 | 89.2 (75.3 to 95.7) | 7.9 (2.7 to 20.8) | 5.1 (1.4 to 16.9) |
| 5-11 Years, ST4: Day 208 | 97.4 (86.5 to 99.5) | 100 (90.6 to 100) | 5.1 (1.4 to 16.9) |
| 5-11 Years, ST4: Day 365 | 85.7 (70.6 to 93.7) | 75.7 (59.9 to 86.6) | 0.0 (0.0 to 9.9) |
| 5-11 Years, ST4: Month 18 | 48.6 (33.0 to 64.4) | 29.4 (16.8 to 46.2) | 0.0 (0.0 to 9.4) |
| 5-11 Years, ST5: Day 85 | 97.4 (86.5 to 99.5) | 8.8 (3.0 to 23.0) | 5.3 (1.5 to 17.3) |
| 5-11 Years, ST5: Day 180 | 91.9 (78.7 to 97.2) | 5.3 (1.5 to 17.3) | 5.1 (1.4 to 16.9) |
| 5-11 Years, ST5: Day 208 | 97.4 (86.5 to 99.5) | 100 (90.6 to 100) | 7.7 (2.7 to 20.3) |
| 5-11 Years, ST5: Day 365 | 91.4 (77.6 to 97.0) | 64.9 (48.8 to 78.2) | 0.0 (0.0 to 9.9) |
| 5-11 Years, ST5: Month 18 | 42.9 (28.0 to 59.1) | 29.4 (16.8 to 46.2) | 0.0 (0.0 to 9.4) |
| 5-11 Years, ST6: Day 85 | 94.9 (83.1 to 98.6) | 8.8 (3.0 to 23.0) | 2.6 (0.5 to 13.5) |
| 5-11 Years, ST6: Day 180 | 78.9 (63.7 to 88.9) | 13.2 (5.8 to 27.3) | 5.1 (1.4 to 16.9) |
| 5-11 Years, ST6: Day 208 | 94.9 (83.1 to 98.6) | 100 (90.6 to 100) | 7.7 (2.7 to 20.3) |
| 5-11 Years, ST6: Day 365 | 83.3 (68.1 to 92.1) | 73.0 (57.0 to 84.6) | 0.0 (0.0 to 9.9) |
| 5-11 Years, ST6: Month 18 | 27.8 (15.8 to 44.0) | 32.4 (19.1 to 49.2) | 0.0 (0.0 to 9.4) |
| 12-17 Years, ST1: Day 85 | 91.9 (78.7 to 97.2) | 5.0 (1.4 to 16.5) | 0.0 (0.0 to 9.0) |
| 12-17 Years, ST1: Day 180 | 59.0 (43.4 to 72.9) | 12.5 (5.5 to 26.1) | 7.3 (2.5 to 19.4) |
| 12-17 Years, ST1: Day 208 | 97.4 (86.8 to 99.5) | 97.5 (87.1 to 99.6) | 5.3 (1.5 to 17.3) |
| 12-17 Years, ST1: Day 365 | 48.6 (33.0 to 64.4) | 44.7 (30.1 to 60.3) | 0.0 (0.0 to 9.6) |
| 12-17 Years, ST1: Month 18 | 27.8 (15.8 to 44.0) | 16.2 (7.7 to 31.1) | 0.0 (0.0 to 10.2) |
| 12-17 Years, ST2: Day 85 | 94.6 (82.3 to 98.5) | 10.0 (4.0 to 23.1) | 0.0 (0.0 to 9.0) |
| 12-17 Years, ST2: Day 180 | 82.1 (67.3 to 91.0) | 17.5 (8.7 to 31.9) | 4.9 (1.3 to 16.1) |
| 12-17 Years, ST2: Day 208 | 100 (91.0 to 100) | 97.5 (87.1 to 99.6) | 2.6 (0.5 to 13.5) |
| 12-17 Years, ST2: Day 365 | 65.7 (49.2 to 79.2) | 71.1 (55.2 to 83.0) | 2.8 (0.5 to 14.2) |
| 12-17 Years, ST2: Month 18 | 41.7 (27.1 to 57.8) | 48.6 (33.4 to 64.1) | 0.0 (0.0 to 10.2) |
| 12-17 Years, ST3: Day 85 | 94.6 (82.3 to 98.5) | 17.5 (8.7 to 31.9) | 0.0 (0.0 to 9.0) |
| 12-17 Years, ST3: Day 180 | 84.6 (70.3 to 92.8) | 17.5 (8.7 to 31.9) | 7.3 (2.5 to 19.4) |
| 12-17 Years, ST3: Day 208 | 100 (91.0 to 100) | 97.5 (87.1 to 99.6) | 7.9 (2.7 to 20.8) |
| 12-17 Years, ST3: Day 365 | 71.4 (54.9 to 83.7) | 78.9 (63.7 to 88.9) | 0.0 (0.0 to 9.6) |
| 12-17 Years, ST3: Month 18 | 38.9 (24.8 to 55.1) | 54.1 (38.4 to 69.0) | 0.0 (0.0 to 10.2) |
| 12-17 Years, ST4: Day 85 | 97.3 (86.2 to 99.5) | 5.0 (1.4 to 16.5) | 0.0 (0.0 to 9.0) |
| 12-17 Years, ST4: Day 180 | 79.5 (64.5 to 89.2) | 10.0 (4.0 to 23.1) | 4.9 (1.3 to 16.1) |
| 12-17 Years, ST4: Day 208 | 100 (91.0 to 100) | 97.5 (87.1 to 99.6) | 7.9 (2.7 to 20.8) |
| 12-17 Years, ST4: Day 365 | 65.7 (49.2 to 79.2) | 55.3 (39.7 to 69.9) | 0.0 (0.0 to 9.6) |
| 12-17 Years, ST4: Month 18 | 44.4 (29.5 to 60.4) | 29.7 (17.5 to 45.8) | 0.0 (0.0 to 10.2) |
| 12-17 Years, ST5: Day 85 | 94.6 (82.3 to 98.5) | 7.5 (2.6 to 19.9) | 2.6 (0.5 to 13.2) |
| 12-17 Years, ST5: Day 180 | 74.4 (58.9 to 85.4) | 12.5 (5.5 to 26.1) | 2.4 (0.4 to 12.6) |
| 12-17 Years, ST5: Day 208 | 100 (91.0 to 100) | 97.5 (87.1 to 99.6) | 5.3 (1.5 to 17.3) |
| 12-17 Years, ST5: Day 365 | 65.7 (49.2 to 79.2) | 63.2 (47.3 to 76.6) | 0.0 (0.0 to 9.6) |
| 12-17 Years, ST5: Month 18 | 33.3 (20.2 to 49.7) | 24.3 (13.4 to 40.1) | 2.9 (0.5 to 14.9) |
| 12-17 Years, ST6: Day 85 | 91.9 (78.7 to 97.2) | 5.0 (1.4 to 16.5) | 0.0 (0.0 to 9.0) |
| 12-17 Years, ST6: Day 180 | 66.7 (51.0 to 79.4) | 15.0 (7.1 to 29.1) | 7.3 (2.5 to 19.4) |
| 12-17 Years, ST6: Day 208 | 100 (91.0 to 100) | 95.0 (83.5 to 98.6) | 10.5 (4.2 to 24.1) |
| 12-17 Years, ST6: Day 365 | 68.6 (52.0 to 81.4) | 52.6 (37.3 to 67.5) | 2.8 (0.5 to 14.2) |
| 12-17 Years, ST6: Month 18 | 33.3 (20.2 to 49.7) | 21.6 (11.4 to 37.2) | 2.9 (0.5 to 14.9) |
| 18-65 Years, ST1: Day 85 | 59.1 (49.0 to 68.6) | 1.2 (0.2 to 6.7) | 2.2 (0.6 to 7.5) |
| 18-65 Years, ST1: Day 180 | 22.1 (14.9 to 31.4) | 2.4 (0.7 to 8.4) | 2.2 (0.6 to 7.6) |
| 18-65 Years, ST1: Day 194 | 92.2 (81.5 to 96.9) | 65.9 (51.1 to 78.1) | 4.5 (1.3 to 15.1) |
| 18-65 Years, ST1: Day 208 | 89.2 (81.3 to 94.1) | 70.4 (59.7 to 79.2) | 9.1 (4.7 to 16.9) |
| 18-65 Years, ST1: Day 365 | 32.6 (23.9 to 42.7) | 11.1 (6.0 to 19.8) | 1.1 (0.2 to 6.2) |
| 18-65 Years, ST1: Month 18 | 10.5 (5.6 to 18.7) | 6.8 (3.0 to 15.1) | 0.0 (0.0 to 4.3) |
| 18-65 Years, ST2: Day 85 | 84.9 (76.3 to 90.8) | 2.5 (0.7 to 8.6) | 0.0 (0.0 to 4.0) |
| 18-65 Years, ST2: Day 180 | 49.5 (39.6 to 59.4) | 3.6 (1.2 to 10.1) | 0.0 (0.0 to 4.0) |
| 18-65 Years, ST2: Day 194 | 100 (93.0 to 100) | 88.6 (76.0 to 95.0) | 2.3 (0.4 to 11.8) |
| 18-65 Years, ST2: Day 208 | 96.8 (90.9 to 98.9) | 90.1 (81.7 to 94.9) | 2.3 (0.6 to 7.9) |
| 18-65 Years, ST2: Day 365 | 54.3 (44.2 to 64.1) | 42.0 (31.8 to 52.8) | 1.1 (0.2 to 6.2) |
| 18-65 Years, ST2: Month 18 | 25.6 (17.5 to 35.7) | 13.7 (7.6 to 23.4) | 0.0 (0.0 to 4.3) |
| 18-65 Years, ST3: Day 85 | 86.0 (77.5 to 91.6) | 4.9 (1.9 to 12.0) | 0.0 (0.0 to 4.0) |
| 18-65 Years, ST3: Day 180 | 45.3 (35.6 to 55.3) | 3.6 (1.2 to 10.1) | 4.3 (1.7 to 10.7) |
| 18-65 Years, ST3: Day 194 | 100 (93.0 to 100) | 86.4 (73.3 to 93.6) | 4.5 (1.3 to 15.1) |
| 18-65 Years, ST3: Day 208 | 98.9 (94.2 to 99.8) | 85.2 (75.9 to 91.3) | 3.4 (1.2 to 9.5) |
| 18-65 Years, ST3: Day 365 | 53.3 (43.1 to 63.1) | 39.5 (29.6 to 50.4) | 1.1 (0.2 to 6.2) |
| 18-65 Years, ST3: Month 18 | 18.6 (11.8 to 28.1) | 19.2 (11.8 to 29.7) | 0.0 (0.0 to 4.3) |
| 18-65 Years, ST4: Day 85 | 73.1 (63.3 to 81.1) | 2.5 (0.7 to 8.6) | 2.2 (0.6 to 7.5) |
| 18-65 Years, ST4: Day 180 | 31.6 (23.1 to 41.5) | 7.2 (3.4 to 14.9) | 7.6 (3.7 to 14.9) |
| 18-65 Years, ST4: Day 194 | 98.0 (89.7 to 99.7) | 77.3 (63.0 to 87.2) | 6.8 (2.3 to 18.2) |
| 18-65 Years, ST4: Day 208 | 93.5 (86.6 to 97.0) | 79.0 (68.9 to 86.5) | 6.8 (3.2 to 14.1) |
| 18-65 Years, ST4: Day 365 | 43.5 (33.8 to 53.7) | 22.2 (14.5 to 32.4) | 2.3 (0.6 to 8.0) |
| 18-65 Years, ST4: Month 18 | 18.6 (11.8 to 28.1) | 9.6 (4.7 to 18.5) | 2.4 (0.6 to 8.2) |
| 18-65 Years, ST5: Day 85 | 72.0 (62.2 to 80.1) | 1.2 (0.2 to 6.7) | 1.1 (0.2 to 5.8) |
| 18-65 Years, ST5: Day 180 | 37.9 (28.8 to 47.9) | 2.4 (0.7 to 8.4) | 4.3 (1.7 to 10.7) |
| 18-65 Years, ST5: Day 194 | 98.0 (89.7 to 99.7) | 77.3 (63.0 to 87.2) | 4.5 (1.3 to 15.1) |
| 18-65 Years, ST5: Day 208 | 95.7 (89.5 to 98.3) | 75.3 (64.9 to 83.4) | 6.8 (3.2 to 14.1) |
| 18-65 Years, ST5: Day 365 | 41.3 (31.8 to 51.5) | 24.7 (16.6 to 35.1) | 2.3 (0.6 to 8.0) |
| 18-65 Years, ST5: Month 18 | 11.6 (6.4 to 20.1) | 8.2 (3.8 to 16.8) | 1.2 (0.2 to 6.4) |
| 18-65 Years, ST6: Day 85 | 68.8 (58.8 to 77.3) | 2.5 (0.7 to 8.6) | 3.2 (1.1 to 9.1) |
| 18-65 Years, ST6: Day 180 | 31.6 (23.1 to 41.5) | 3.6 (1.2 to 10.1) | 4.3 (1.7 to 10.7) |
| 18-65 Years, ST6: Day 194 | 98.0 (89.7 to 99.7) | 77.3 (63.0 to 87.2) | 6.8 (2.3 to 18.2) |
| 18-65 Years, ST6: Day 208 | 93.5 (86.6 to 97.0) | 74.1 (63.6 to 82.4) | 8.0 (3.9 to 15.5) |
| 18-65 Years, ST6: Day 365 | 42.4 (32.8 to 52.6) | 22.2 (14.5 to 32.4) | 4.6 (1.8 to 11.2) |
| 18-65 Years, ST6: Month 18 | 15.1 (9.1 to 24.2) | 6.8 (3.0 to 15.1) | 3.5 (1.2 to 9.9) |
GMFR for IgG when compared to baseline against each OspA serotype ST1 to ST6, stratified by age group (5-11, 12-17 and 18-65 years) determined by IgG binding assay at Day 85 and Day 208 were evaluated.
| Fold rise | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| 5-11 Years, ST1: Day 85 | 12.3 (9.8 to 15.3) | 1.0 (1.0 to 1.1) | 1.0 (0.8 to 1.2) |
| 5-11 Years, ST1: Day 208 | 32.3 (24.3 to 42.9) | 25.7 (17.8 to 37.1) | 1.0 (0.8 to 1.2) |
| 5-11 Years, ST2: Day 85 | 30.2 (23.4 to 39.0) | 1.2 (1.0 to 1.3) | 1.0 (0.8 to 1.2) |
| 5-11 Years, ST2: Day 208 | 66.9 (50.5 to 88.6) | 60.7 (44.9 to 81.9) | 1.0 (0.8 to 1.2) |
| 5-11 Years, ST3: Day 85 | 30.7 (23.1 to 40.8) | 1.2 (1.0 to 1.4) | 1.0 (0.9 to 1.2) |
| 5-11 Years, ST3: Day 208 | 54.7 (40.5 to 74.0) | 65.1 (47.1 to 89.9) | 1.0 (0.8 to 1.2) |
| 5-11 Years, ST4: Day 85 | 16.9 (13.0 to 22.1) | 1.1 (1.0 to 1.3) | 1.0 (0.8 to 1.2) |
| 5-11 Years, ST4: Day 208 | 43.9 (33.0 to 58.6) | 33.1 (23.7 to 46.4) | 1.0 (0.8 to 1.3) |
| 5-11 Years, ST5: Day 85 | 21.7 (16.6 to 28.4) | 1.1 (1.0 to 1.2) | 1.0 (0.9 to 1.3) |
| 5-11 Years, ST5: Day 208 | 49.6 (37.3 to 65.9) | 34.5 (24.9 to 47.7) | 1.1 (0.9 to 1.3) |
| 5-11 Years, ST6: Day 85 | 14.4 (10.9 to 19.0) | 1.1 (1.0 to 1.2) | 1.0 (0.8 to 1.2) |
| 5-11 Years, ST6: Day 208 | 38.8 (26.9 to 56.0) | 31.5 (22.4 to 44.3) | 1.1 (0.9 to 1.4) |
| 12-17 Years, ST1: Day 85 | 9.9 (6.8 to 14.4) | 1.0 (1.0 to 1.1) | 1.0 (0.9 to 1.0) |
| 12-17 Years, ST1: Day 208 | 25.4 (18.1 to 35.7) | 23.4 (15.7 to 34.8) | 1.1 (1.0 to 1.2) |
| 12-17 Years, ST2: Day 85 | 20.7 (14.2 to 30.2) | 1.2 (1.0 to 1.4) | 1.0 (1.0 to 1.0) |
| 12-17 Years, ST2: Day 208 | 45.2 (34.8 to 58.8) | 45.3 (31.0 to 66.4) | 1.0 (1.0 to 1.1) |
| 12-17 Years, ST3: Day 85 | 21.3 (14.4 to 31.6) | 1.2 (1.1 to 1.4) | 1.0 (0.9 to 1.0) |
| 12-17 Years, ST3: Day 208 | 43.9 (32.5 to 59.3) | 46.9 (31.3 to 70.2) | 1.0 (1.0 to 1.1) |
| 12-17 Years, ST4: Day 85 | 12.8 (9.1 to 18.2) | 1.1 (1.0 to 1.2) | 1.0 (0.9 to 1.0) |
| 12-17 Years, ST4: Day 208 | 32.0 (23.8 to 43.0) | 26.1 (17.7 to 38.4) | 1.1 (1.0 to 1.2) |
| 12-17 Years, ST5: Day 85 | 13.7 (9.5 to 19.7) | 1.1 (1.0 to 1.2) | 1.0 (0.9 to 1.1) |
| 12-17 Years, ST5: Day 208 | 31.7 (24.1 to 41.7) | 25.8 (17.7 to 37.7) | 1.0 (0.9 to 1.2) |
| 12-17 Years, ST6: Day 85 | 11.2 (7.8 to 16.2) | 1.1 (1.0 to 1.2) | 1.0 (0.9 to 1.0) |
| 12-17 Years, ST6: Day 208 | 30.0 (22.5 to 39.9) | 19.7 (13.4 to 28.8) | 1.1 (1.0 to 1.3) |
| 18-65 Years, ST1: Day 85 | 3.1 (2.4 to 3.9) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST1: Day 208 | 9.4 (7.2 to 12.2) | 4.0 (3.1 to 5.3) | 1.1 (1.0 to 1.3) |
| 18-65 Years, ST2: Day 85 | 7.2 (5.7 to 9.1) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST2: Day 208 | 19.7 (15.9 to 24.4) | 10.6 (8.1 to 13.7) | 1.0 (0.9 to 1.1) |
| 18-65 Years, ST3: Day 85 | 6.5 (5.1 to 8.2) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST3: Day 208 | 17.7 (14.3 to 22.0) | 9.0 (6.8 to 11.8) | 1.1 (1.0 to 1.2) |
| 18-65 Years, ST4: Day 85 | 3.8 (3.1 to 4.8) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST4: Day 208 | 11.9 (9.5 to 15.0) | 5.2 (4.0 to 6.7) | 1.1 (1.0 to 1.2) |
| 18-65 Years, ST5: Day 85 | 4.2 (3.3 to 5.2) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST5: Day 208 | 12.7 (10.3 to 15.8) | 4.9 (3.8 to 6.4) | 1.1 (1.0 to 1.2) |
| 18-65 Years, ST6: Day 85 | 3.6 (2.9 to 4.5) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) |
| 18-65 Years, ST6: Day 208 | 11.6 (9.2 to 14.7) | 4.6 (3.6 to 5.9) | 1.1 (1.0 to 1.2) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay were evaluated.
| Titers | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| ST1: Month 18 | 27.3 (24.2 to 30.7) | 22.7 (21.3 to 24.2) | 21.2 (20.2 to 22.3) |
| ST1: Month 19 | 1057.0 (843.1 to 1325.1) | 830.0 (621.3 to 1108.9) | 20.9 (20.0 to 21.9) |
| ST1: Month 23 | 178.2 (142.9 to 222.2) | 136.9 (107.3 to 174.6) | 21.4 (20.1 to 22.9) |
| ST1: Month 26 | 91.0 (74.4 to 111.4) | 71.1 (56.3 to 89.8) | 21.9 (20.5 to 23.4) |
| ST1: Month 30 | 61.1 (49.0 to 76.2) | 52.6 (42.0 to 65.7) | 20.3 (19.7 to 20.9) |
| ST1: Month 31 | 1193.1 (967.1 to 1471.8) | 941.4 (729.8 to 1214.4) | 21.0 (19.0 to 23.3) |
| ST1: Month 39 | 97.3 (81.5 to 116.2) | 89.5 (69.7 to 114.8) | 21.2 (19.6 to 23.1) |
| ST1: Month 42 | 78.3 (66.1 to 92.6) | 68.6 (54.6 to 86.2) | 20.6 (19.7 to 21.6) |
| ST1: Month 43 | 1044.8 (888.5 to 1228.5) | 969.8 (768.9 to 1223.2) | 21.5 (19.1 to 24.2) |
| ST1: Month 48 | 201.1 (159.9 to 252.8) | 173.8 (136.8 to 220.9) | 20.0 (20.0 to 20.0) |
| ST2: Month 18 | 35.4 (31.1 to 40.2) | 30.3 (27.2 to 33.8) | 20.3 (19.9 to 20.9) |
| ST2: Month 19 | 1807.9 (1486.2 to 2199.3) | 1603.1 (1239.7 to 2073.0) | 20.5 (19.8 to 21.2) |
| ST2: Month 23 | 350.5 (294.0 to 417.9) | 282.6 (228.2 to 349.9) | 20.9 (19.8 to 22.1) |
| ST2: Month 26 | 177.1 (148.6 to 211.0) | 140.6 (112.7 to 175.6) | 21.5 (20.3 to 22.8) |
| ST2: Month 30 | 106.9 (85.8 to 133.2) | 95.2 (76.4 to 118.5) | 20.3 (19.7 to 20.8) |
| ST2: Month 31 | 1788.6 (1501.0 to 2131.2) | 1489.7 (1197.1 to 1853.8) | 21.4 (19.2 to 23.9) |
| ST2: Month 39 | 172.5 (144.4 to 206.0) | 150.3 (118.7 to 190.3) | 20.8 (19.5 to 22.2) |
| ST2: Month 42 | 132.9 (110.9 to 159.3) | 115.5 (92.7 to 143.9) | 20.5 (19.5 to 21.6) |
| ST2: Month 43 | 1622.3 (1407.9 to 1869.4) | 1555.9 (1253.9 to 1930.7) | 21.2 (18.9 to 23.9) |
| ST2: Month 48 | 324.6 (264.4 to 398.5) | 306.0 (250.4 to 373.8) | 20.0 (20.0 to 20.0) |
| ST3: Month 18 | 34.3 (29.8 to 39.4) | 33.8 (30.1 to 37.9) | 20.1 (19.9 to 20.3) |
| ST3: Month 19 | 1628.0 (1331.6 to 1990.2) | 1418.0 (1094.3 to 1837.4) | 20.8 (20.1 to 21.6) |
| ST3: Month 23 | 319.5 (261.3 to 390.8) | 283.6 (225.2 to 357.2) | 21.0 (19.7 to 22.4) |
| ST3: Month 26 | 160.9 (133.7 to 193.5) | 143.9 (114.7 to 180.6) | 21.6 (20.3 to 23.0) |
| ST3: Month 30 | 97.9 (77.6 to 123.6) | 102.6 (82.0 to 128.2) | 21.2 (20.2 to 22.2) |
| ST3: Month 31 | 1592.0 (1327.3 to 1909.6) | 1396.0 (1099.7 to 1772.2) | 21.9 (19.6 to 24.5) |
| ST3: Month 39 | 155.5 (129.6 to 186.6) | 151.9 (117.7 to 196.0) | 21.5 (19.3 to 23.9) |
| ST3: Month 42 | 118.6 (99.0 to 142.0) | 119.1 (95.4 to 148.7) | 20.7 (19.7 to 21.8) |
| ST3: Month 43 | 1388.1 (1192.5 to 1615.9) | 1393.0 (1104.4 to 1756.9) | 21.8 (19.3 to 24.5) |
| ST3: Month 48 | 320.2 (258.0 to 397.5) | 317.4 (253.5 to 397.4) | 20.7 (19.7 to 21.8) |
| ST4: Month 18 | 32.3 (28.5 to 36.7) | 25.8 (23.7 to 28.1) | 21.0 (20.1 to 22.0) |
| ST4: Month 19 | 1334.1 (1086.0 to 1639.0) | 1032.9 (786.1 to 1357.3) | 21.7 (20.5 to 23.0) |
| ST4: Month 23 | 227.5 (185.0 to 279.8) | 170.4 (135.1 to 215.0) | 22.0 (20.3 to 23.8) |
| ST4: Month 26 | 122.9 (102.6 to 147.2) | 90.6 (72.4 to 113.5) | 22.7 (21.0 to 24.6) |
| ST4: Month 30 | 81.1 (65.3 to 100.7) | 63.9 (51.4 to 79.5) | 21.4 (20.0 to 22.9) |
| ST4: Month 31 | 1493.2 (1242.7 to 1794.2) | 1123.3 (877.9 to 1437.2) | 23.2 (20.5 to 26.3) |
| ST4: Month 39 | 125.1 (104.5 to 149.7) | 113.6 (89.1 to 144.9) | 21.9 (19.7 to 24.4) |
| ST4: Month 42 | 101.8 (85.6 to 121.1) | 88.0 (70.1 to 110.4) | 21.9 (20.2 to 23.8) |
| ST4: Month 43 | 1327.6 (1143.7 to 1541.0) | 1199.4 (964.0 to 1492.3) | 22.5 (19.8 to 25.6) |
| ST4: Month 48 | 260.0 (209.3 to 323.0) | 226.7 (184.2 to 279.1) | 20.6 (19.5 to 21.7) |
| ST5: Month 18 | 29.3 (25.9 to 33.1) | 24.9 (23.0 to 27.0) | 20.2 (19.9 to 20.5) |
| ST5: Month 19 | 1266.2 (1024.3 to 1565.2) | 980.1 (745.0 to 1289.4) | 20.2 (19.8 to 20.7) |
| ST5: Month 23 | 226.5 (186.1 to 275.7) | 150.6 (117.6 to 193.0) | 21.0 (19.8 to 22.2) |
| ST5: Month 26 | 121.5 (101.1 to 146.1) | 86.6 (69.2 to 108.4) | 21.6 (20.3 to 23.0) |
| ST5: Month 30 | 72.6 (57.8 to 91.2) | 65.7 (52.8 to 81.7) | 20.3 (19.7 to 20.9) |
| ST5: Month 31 | 1354.6 (1130.8 to 1622.7) | 1044.5 (829.9 to 1314.7) | 22.1 (19.7 to 24.9) |
| ST5: Month 39 | 119.8 (100.7 to 142.7) | 106.7 (84.5 to 134.9) | 21.4 (19.6 to 23.4) |
| ST5: Month 42 | 91.8 (77.1 to 109.3) | 83.7 (67.7 to 103.5) | 20.3 (19.7 to 20.9) |
| ST5: Month 43 | 1195.4 (1030.9 to 1386.3) | 1097.4 (884.8 to 1361.1) | 21.5 (19.1 to 24.2) |
| ST5: Month 48 | 226.0 (181.5 to 281.4) | 181.2 (141.0 to 232.9) | 20.3 (19.7 to 21.0) |
| ST6: Month 18 | 32.2 (28.1 to 36.9) | 25.7 (23.5 to 28.0) | 21.2 (20.4 to 22.1) |
| ST6: Month 19 | 1254.9 (1020.7 to 1542.8) | 957.2 (726.8 to 1260.5) | 22.3 (21.0 to 23.7) |
| ST6: Month 23 | 226.3 (184.3 to 277.8) | 165.7 (131.3 to 209.0) | 22.2 (20.7 to 23.9) |
| ST6: Month 26 | 128.0 (106.5 to 153.9) | 88.6 (70.9 to 110.7) | 22.6 (21.0 to 24.2) |
| ST6: Month 30 | 76.3 (60.7 to 95.9) | 67.3 (54.3 to 83.5) | 22.1 (20.6 to 23.7) |
| ST6: Month 31 | 1358.1 (1132.7 to 1628.3) | 1026.8 (813.9 to 1295.3) | 23.5 (20.7 to 26.7) |
| ST6: Month 39 | 124.0 (103.4 to 148.8) | 103.7 (81.8 to 131.4) | 22.1 (20.0 to 24.5) |
| ST6: Month 42 | 98.2 (81.8 to 118.0) | 82.7 (66.2 to 103.5) | 20.8 (19.7 to 22.0) |
| ST6: Month 43 | 1195.8 (1028.0 to 1391.0) | 1072.7 (862.9 to 1333.6) | 22.4 (19.8 to 25.4) |
| ST6: Month 48 | 240.9 (192.4 to 301.7) | 203.7 (164.6 to 252.2) | 21.0 (19.8 to 22.3) |
Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| ST1: Month 18 | 16.6 (11.6 to 23.2) | 9.7 (5.9 to 15.7) | 0.0 (0.0 to 2.4) |
| ST1: Month 19 | 96.8 (92.1 to 98.8) | 94.6 (88.7 to 97.5) | 0.0 (0.0 to 3.0) |
| ST1: Month 23 | 87.8 (80.6 to 92.6) | 80.7 (72.3 to 87.0) | 1.7 (0.5 to 6.0) |
| ST1: Month 26 | 75.5 (66.6 to 82.5) | 62.1 (52.5 to 70.9) | 3.6 (1.4 to 8.8) |
| ST1: Month 30 | 57.9 (48.5 to 66.9) | 49.5 (39.7 to 59.3) | 0.0 (0.0 to 3.8) |
| ST1: Month 31 | 97.3 (92.5 to 99.1) | 98.0 (92.9 to 99.4) | 1.0 (0.2 to 5.6) |
| ST1: Month 39 | 80.4 (71.9 to 86.8) | 71.1 (60.6 to 79.7) | 2.3 (0.6 to 8.1) |
| ST1: Month 42 | 77.1 (68.2 to 84.1) | 67.1 (56.3 to 76.3) | 2.4 (0.6 to 8.2) |
| ST1: Month 43 | 100 (96.7 to 100) | 98.9 (94.0 to 99.8) | 2.3 (0.6 to 7.9) |
| ST1: Month 48 | 92.4 (85.1 to 96.3) | 93.7 (86.0 to 97.3) | 0.0 (0.0 to 4.9) |
| ST2: Month 18 | 36.3 (29.2 to 44.1) | 31.3 (24.2 to 39.2) | 0.0 (0.0 to 2.4) |
| ST2: Month 19 | 97.6 (93.2 to 99.2) | 96.4 (91.1 to 98.6) | 0.0 (0.0 to 3.0) |
| ST2: Month 23 | 96.5 (91.4 to 98.6) | 92.7 (86.2 to 96.2) | 0.8 (0.1 to 4.6) |
| ST2: Month 26 | 91.8 (85.2 to 95.6) | 81.6 (73.0 to 87.9) | 4.5 (1.9 to 10.0) |
| ST2: Month 30 | 78.5 (69.8 to 85.2) | 74.2 (64.7 to 81.9) | 1.0 (0.2 to 5.6) |
| ST2: Month 31 | 99.1 (95.2 to 99.8) | 99.0 (94.4 to 99.8) | 2.1 (0.6 to 7.2) |
| ST2: Month 39 | 90.7 (83.6 to 94.8) | 84.3 (75.0 to 90.6) | 2.3 (0.6 to 8.1) |
| ST2: Month 42 | 85.7 (77.8 to 91.1) | 81.7 (72.0 to 88.6) | 1.2 (0.2 to 6.4) |
| ST2: Month 43 | 100 (96.7 to 100) | 98.9 (94.0 to 99.8) | 1.1 (0.2 to 6.2) |
| ST2: Month 48 | 94.6 (87.9 to 97.7) | 97.5 (91.2 to 99.3) | 0.0 (0.0 to 4.9) |
| ST3: Month 18 | 31.2 (24.5 to 38.8) | 40.3 (32.6 to 48.4) | 0.6 (0.1 to 3.5) |
| ST3: Month 19 | 97.6 (93.2 to 99.2) | 96.4 (91.1 to 98.6) | 2.4 (0.8 to 6.9) |
| ST3: Month 23 | 93.0 (86.9 to 96.4) | 91.7 (85.0 to 95.6) | 1.7 (0.5 to 6.0) |
| ST3: Month 26 | 90.0 (83.0 to 94.3) | 85.4 (77.4 to 91.0) | 5.4 (2.5 to 11.2) |
| ST3: Month 30 | 74.8 (65.8 to 82.0) | 78.4 (69.2 to 85.4) | 6.2 (2.9 to 12.8) |
| ST3: Month 31 | 99.1 (95.2 to 99.8) | 99.0 (94.4 to 99.8) | 4.1 (1.6 to 10.1) |
| ST3: Month 39 | 90.7 (83.6 to 94.8) | 84.3 (75.0 to 90.6) | 2.3 (0.6 to 8.1) |
| ST3: Month 42 | 88.6 (81.1 to 93.3) | 86.6 (77.6 to 92.3) | 2.4 (0.6 to 8.2) |
| ST3: Month 43 | 100 (96.7 to 100) | 98.9 (94.0 to 99.8) | 3.4 (1.2 to 9.5) |
| ST3: Month 48 | 95.7 (89.3 to 98.3) | 96.2 (89.4 to 98.7) | 2.7 (0.7 to 9.2) |
| ST4: Month 18 | 31.2 (24.5 to 38.8) | 19.4 (13.8 to 26.7) | 1.3 (0.4 to 4.6) |
| ST4: Month 19 | 97.6 (93.2 to 99.2) | 94.6 (88.7 to 97.5) | 3.3 (1.3 to 8.1) |
| ST4: Month 23 | 91.3 (84.7 to 95.2) | 88.1 (80.7 to 92.9) | 2.5 (0.9 to 7.2) |
| ST4: Month 26 | 86.4 (78.7 to 91.6) | 72.8 (63.5 to 80.5) | 7.1 (3.7 to 13.5) |
| ST4: Month 30 | 72.9 (63.8 to 80.4) | 60.8 (50.9 to 69.9) | 1.0 (0.2 to 5.6) |
| ST4: Month 31 | 99.1 (95.2 to 99.8) | 98.0 (92.9 to 99.4) | 3.1 (1.1 to 8.7) |
| ST4: Month 39 | 85.0 (77.1 to 90.6) | 80.7 (71.0 to 87.8) | 2.3 (0.6 to 8.1) |
| ST4: Month 42 | 82.9 (74.5 to 88.9) | 74.4 (64.0 to 82.6) | 4.7 (1.8 to 11.5) |
| ST4: Month 43 | 100 (96.7 to 100) | 98.9 (94.0 to 99.8) | 4.5 (1.8 to 11.1) |
| ST4: Month 48 | 94.6 (87.9 to 97.7) | 98.7 (93.2 to 99.8) | 0.0 (0.0 to 4.9) |
| ST5: Month 18 | 23.6 (17.6 to 30.8) | 17.4 (12.0 to 24.4) | 1.3 (0.4 to 4.6) |
| ST5: Month 19 | 96.8 (92.1 to 98.8) | 94.6 (88.7 to 97.5) | 0.8 (0.1 to 4.5) |
| ST5: Month 23 | 91.3 (84.7 to 95.2) | 78.0 (69.3 to 84.7) | 2.5 (0.9 to 7.2) |
| ST5: Month 26 | 85.5 (77.7 to 90.8) | 68.0 (58.4 to 76.2) | 5.4 (2.5 to 11.2) |
| ST5: Month 30 | 61.7 (52.2 to 70.3) | 60.8 (50.9 to 69.9) | 1.0 (0.2 to 5.6) |
| ST5: Month 31 | 99.1 (95.2 to 99.8) | 99.0 (94.4 to 99.8) | 4.1 (1.6 to 10.1) |
| ST5: Month 39 | 86.0 (78.2 to 91.3) | 80.7 (71.0 to 87.8) | 3.5 (1.2 to 9.8) |
| ST5: Month 42 | 80.0 (71.4 to 86.5) | 79.3 (69.3 to 86.6) | 1.2 (0.2 to 6.4) |
| ST5: Month 43 | 100 (96.7 to 100) | 98.9 (94.0 to 99.8) | 2.3 (0.6 to 7.9) |
| ST5: Month 48 | 92.4 (85.1 to 96.3) | 87.3 (78.2 to 93.0) | 1.3 (0.2 to 7.2) |
| ST6: Month 18 | 22.2 (16.4 to 29.2) | 16.7 (11.5 to 23.6) | 2.6 (1.0 to 6.4) |
| ST6: Month 19 | 96.9 (92.2 to 98.8) | 94.6 (88.7 to 97.5) | 4.1 (1.7 to 9.2) |
| ST6: Month 23 | 90.4 (83.7 to 94.6) | 83.5 (75.4 to 89.3) | 2.5 (0.9 to 7.2) |
| ST6: Month 26 | 86.4 (78.7 to 91.6) | 66.0 (56.4 to 74.4) | 7.1 (3.7 to 13.5) |
| ST6: Month 30 | 59.8 (50.3 to 68.6) | 59.8 (49.8 to 69.0) | 4.1 (1.6 to 10.1) |
| ST6: Month 31 | 99.1 (95.2 to 99.8) | 98.0 (92.9 to 99.4) | 3.1 (1.1 to 8.7) |
| ST6: Month 39 | 85.0 (77.1 to 90.6) | 77.1 (67.0 to 84.8) | 4.7 (1.8 to 11.4) |
| ST6: Month 42 | 79.0 (70.3 to 85.7) | 70.7 (60.1 to 79.5) | 2.4 (0.6 to 8.2) |
| ST6: Month 43 | 100 (96.7 to 100) | 98.9 (94.0 to 99.8) | 3.4 (1.2 to 9.5) |
| ST6: Month 48 | 92.4 (85.1 to 96.3) | 93.7 (86.0 to 97.3) | 1.3 (0.2 to 7.2) |
GMFRs for IgG were determined by IgG binding assay for each OspA serotype (ST1-ST6) at Months 19, 31, and 43 relative to the corresponding pre-booster timepoints Months 18, 30, and 42, respectively.
| Fold rise | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| ST1: Month 19 | 38.4 (31.0 to 47.7) | 36.5 (27.7 to 48.1) | 1.0 (1.0 to 1.0) |
| ST1: Month 31 | 19.3 (15.0 to 25.0) | 19.1 (15.0 to 24.5) | 1.0 (0.9 to 1.2) |
| ST1: Month 43 | 13.3 (11.3 to 15.7) | 14.3 (11.5 to 17.7) | 1.0 (0.9 to 1.2) |
| ST2: Month 19 | 50.6 (41.7 to 61.5) | 53.7 (42.3 to 68.2) | 1.0 (1.0 to 1.0) |
| ST2: Month 31 | 16.2 (12.9 to 20.3) | 15.9 (12.9 to 19.5) | 1.1 (1.0 to 1.2) |
| ST2: Month 43 | 12.2 (10.3 to 14.4) | 13.6 (10.8 to 17.0) | 1.0 (0.9 to 1.2) |
| ST3: Month 19 | 46.7 (38.3 to 57.1) | 44.9 (35.6 to 56.6) | 1.0 (1.0 to 1.1) |
| ST3: Month 31 | 16.6 (13.2 to 21.1) | 14.1 (11.5 to 17.2) | 1.0 (0.9 to 1.2) |
| ST3: Month 43 | 11.6 (10.0 to 13.5) | 11.6 (9.4 to 14.3) | 1.1 (0.9 to 1.2) |
| ST4: Month 19 | 40.1 (32.6 to 49.2) | 40.9 (31.5 to 53.0) | 1.0 (1.0 to 1.1) |
| ST4: Month 31 | 18.1 (14.3 to 23.0) | 18.1 (14.6 to 22.5) | 1.1 (1.0 to 1.2) |
| ST4: Month 43 | 13.1 (11.1 to 15.4) | 13.6 (11.0 to 17.0) | 1.1 (0.9 to 1.2) |
| ST5: Month 19 | 41.3 (33.5 to 50.9) | 40.5 (31.3 to 52.4) | 1.0 (1.0 to 1.0) |
| ST5: Month 31 | 18.5 (14.6 to 23.5) | 16.5 (13.4 to 20.4) | 1.1 (1.0 to 1.2) |
| ST5: Month 43 | 13.0 (11.1 to 15.2) | 13.1 (10.6 to 16.1) | 1.1 (1.0 to 1.2) |
| ST6: Month 19 | 37.2 (30.2 to 45.8) | 37.4 (28.9 to 48.5) | 1.0 (1.0 to 1.1) |
| ST6: Month 31 | 18.2 (14.4 to 23.1) | 15.4 (12.5 to 19.0) | 1.1 (0.9 to 1.2) |
| ST6: Month 43 | 12.0 (10.3 to 14.0) | 13.0 (10.5 to 16.1) | 1.1 (0.9 to 1.2) |
GMTs for IgG against each OspA serotype ST1 to ST6, determined by an IgG binding assay stratified by age group (5-11, 12-17 and 18-65 years) were evaluated.
| Titers | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| 5-11 Years, ST1: Month 18 | 30.8 (23.6 to 40.1) | 23.2 (20.0 to 26.9) | 20.8 (19.2 to 22.6) |
| 5-11 Years, ST1: Month 19 | 1778.9 (1154.1 to 2742.0) | 1415.6 (657.0 to 3049.9) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST1: Month 23 | 230.2 (151.2 to 350.4) | 191.4 (112.3 to 326.4) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST1: Month 26 | 123.0 (83.8 to 180.4) | 85.9 (50.1 to 147.2) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST1: Month 30 | 115.0 (68.6 to 192.7) | 61.6 (36.5 to 103.9) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST1: Month 31 | 1954.0 (1198.9 to 3184.7) | 1353.1 (669.2 to 2736.0) | 24.8 (15.9 to 38.5) |
| 5-11 Years, ST1: Month 39 | 119.6 (79.5 to 179.7) | 200.9 (119.8 to 336.9) | 23.6 (16.7 to 33.6) |
| 5-11 Years, ST1: Month 42 | 113.8 (79.6 to 162.7) | 107.3 (67.7 to 170.0) | 23.5 (18.5 to 29.7) |
| 5-11 Years, ST1: Month 43 | 1752.4 (1280.9 to 2397.4) | 2399.3 (1610.6 to 3574.2) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST1: Month 48 | 342.2 (200.1 to 585.1) | 289.2 (151.4 to 552.7) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST2: Month 18 | 48.7 (36.4 to 65.1) | 39.5 (30.5 to 51.0) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST2: Month 19 | 2988.8 (1955.7 to 4567.7) | 1994.9 (872.8 to 4559.5) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST2: Month 23 | 455.0 (318.2 to 650.6) | 354.9 (199.4 to 631.7) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST2: Month 26 | 273.5 (220.7 to 338.9) | 168.7 (90.0 to 316.2) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST2: Month 30 | 215.5 (145.6 to 319.0) | 118.3 (68.2 to 205.2) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST2: Month 31 | 2802.1 (1724.3 to 4553.5) | 2151.1 (1095.7 to 4223.3) | 25.0 (15.7 to 39.6) |
| 5-11 Years, ST2: Month 39 | 217.0 (142.5 to 330.4) | 280.2 (162.7 to 482.6) | 22.9 (17.2 to 30.5) |
| 5-11 Years, ST2: Month 42 | 185.8 (124.5 to 277.4) | 187.7 (120.3 to 292.8) | 22.8 (17.3 to 30.0) |
| 5-11 Years, ST2: Month 43 | 2631.6 (1989.6 to 3480.7) | 3900.7 (2855.5 to 5328.4) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST2: Month 48 | 570.7 (384.9 to 846.1) | 575.7 (337.1 to 983.2) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST3: Month 18 | 50.0 (36.4 to 68.8) | 50.9 (39.6 to 65.6) | 20.5 (19.5 to 21.5) |
| 5-11 Years, ST3: Month 19 | 2637.1 (1667.7 to 4170.0) | 2046.5 (927.0 to 4518.1) | 21.8 (19.7 to 24.1) |
| 5-11 Years, ST3: Month 23 | 416.4 (281.1 to 616.8) | 417.0 (248.2 to 700.7) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST3: Month 26 | 216.1 (147.4 to 316.8) | 187.6 (107.3 to 327.7) | 20.6 (19.4 to 21.9) |
| 5-11 Years, ST3: Month 30 | 173.9 (102.0 to 296.4) | 155.4 (96.4 to 250.5) | 20.6 (19.3 to 22.1) |
| 5-11 Years, ST3: Month 31 | 2496.3 (1509.5 to 4128.2) | 2158.8 (1109.1 to 4201.9) | 24.9 (15.8 to 39.0) |
| 5-11 Years, ST3: Month 39 | 178.4 (111.2 to 286.2) | 372.4 (215.1 to 644.8) | 24.7 (15.9 to 38.5) |
| 5-11 Years, ST3: Month 42 | 179.7 (117.3 to 275.2) | 186.8 (121.1 to 288.2) | 21.6 (18.4 to 25.3) |
| 5-11 Years, ST3: Month 43 | 2217.9 (1600.7 to 3073.0) | 3824.8 (2719.1 to 5380.1) | 21.8 (19.2 to 24.6) |
| 5-11 Years, ST3: Month 48 | 552.8 (350.8 to 871.1) | 665.8 (396.9 to 1117.0) | 22.1 (17.8 to 27.5) |
| 5-11 Years, ST4: Month 18 | 42.9 (31.3 to 58.8) | 26.6 (22.5 to 31.3) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST4: Month 19 | 2201.9 (1439.7 to 3367.7) | 1501.4 (705.0 to 3197.4) | 21.9 (19.7 to 24.4) |
| 5-11 Years, ST4: Month 23 | 319.4 (221.9 to 459.8) | 227.8 (137.3 to 378.2) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST4: Month 26 | 174.9 (130.3 to 234.8) | 95.1 (55.5 to 163.0) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST4: Month 30 | 148.7 (89.6 to 246.7) | 80.5 (49.1 to 132.0) | 21.1 (18.9 to 23.6) |
| 5-11 Years, ST4: Month 31 | 2343.1 (1449.4 to 3787.7) | 1583.6 (780.5 to 3212.9) | 26.0 (16.7 to 40.5) |
| 5-11 Years, ST4: Month 39 | 147.8 (97.9 to 223.2) | 215.1 (117.8 to 392.5) | 24.0 (16.4 to 35.1) |
| 5-11 Years, ST4: Month 42 | 158.6 (114.1 to 220.5) | 112.3 (63.5 to 198.4) | 23.5 (18.6 to 29.6) |
| 5-11 Years, ST4: Month 43 | 1998.3 (1458.7 to 2737.5) | 2890.2 (2074.0 to 4027.5) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST4: Month 48 | 443.6 (273.2 to 720.3) | 410.0 (240.3 to 699.5) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST5: Month 18 | 38.1 (28.6 to 50.8) | 28.1 (23.2 to 34.1) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST5: Month 19 | 2300.8 (1523.2 to 3475.4) | 1508.5 (689.1 to 3302.0) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST5: Month 23 | 323.0 (219.7 to 474.7) | 217.6 (121.4 to 390.0) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST5: Month 26 | 197.2 (152.7 to 254.5) | 111.2 (63.8 to 193.6) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST5: Month 30 | 147.1 (91.6 to 236.2) | 90.5 (56.1 to 146.0) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST5: Month 31 | 2203.7 (1378.3 to 3523.3) | 1503.5 (776.7 to 2910.5) | 25.1 (15.7 to 40.0) |
| 5-11 Years, ST5: Month 39 | 138.4 (89.1 to 215.1) | 216.9 (120.3 to 391.3) | 23.8 (16.5 to 34.3) |
| 5-11 Years, ST5: Month 42 | 144.2 (104.5 to 198.8) | 114.4 (67.2 to 194.7) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST5: Month 43 | 2019.2 (1494.0 to 2729.1) | 2548.2 (1845.4 to 3518.6) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST5: Month 48 | 391.6 (243.3 to 630.3) | 293.9 (149.8 to 576.8) | 20.0 (20.0 to 20.0) |
| 5-11 Years, ST6: Month 18 | 44.2 (31.1 to 62.8) | 28.8 (23.6 to 35.2) | 20.5 (19.5 to 21.6) |
| 5-11 Years, ST6: Month 19 | 2260.9 (1496.1 to 3416.6) | 1515.5 (691.7 to 3320.4) | 22.8 (20.0 to 25.9) |
| 5-11 Years, ST6: Month 23 | 311.2 (210.4 to 460.5) | 236.5 (129.7 to 431.4) | 21.6 (19.4 to 24.0) |
| 5-11 Years, ST6: Month 26 | 181.3 (139.3 to 236.1) | 117.0 (64.7 to 211.5) | 20.9 (19.1 to 22.8) |
| 5-11 Years, ST6: Month 30 | 137.4 (84.0 to 224.6) | 100.6 (63.5 to 159.5) | 20.9 (19.1 to 22.8) |
| 5-11 Years, ST6: Month 31 | 2172.0 (1355.4 to 3480.6) | 1535.5 (773.0 to 3049.8) | 28.3 (17.7 to 45.3) |
| 5-11 Years, ST6: Month 39 | 153.7 (109.6 to 215.5) | 219.1 (119.2 to 402.6) | 23.9 (16.5 to 34.7) |
| 5-11 Years, ST6: Month 42 | 129.0 (89.0 to 186.9) | 116.4 (65.2 to 207.9) | 21.6 (18.3 to 25.5) |
| 5-11 Years, ST6: Month 43 | 1967.4 (1448.4 to 2672.4) | 2723.5 (2059.6 to 3601.6) | 20.9 (19.1 to 22.9) |
| 5-11 Years, ST6: Month 48 | 396.3 (249.0 to 630.9) | 361.5 (220.5 to 592.5) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST1: Month 18 | 31.0 (22.8 to 42.1) | 24.6 (20.9 to 28.9) | 20.6 (19.4 to 22.0) |
| 12-17 Years, ST1: Month 19 | 1442.0 (899.5 to 2311.5) | 1958.4 (1111.1 to 3451.7) | 20.8 (19.1 to 22.7) |
| 12-17 Years, ST1: Month 23 | 288.3 (189.7 to 438.2) | 220.0 (131.9 to 367.1) | 21.3 (18.7 to 24.3) |
| 12-17 Years, ST1: Month 26 | 122.1 (77.2 to 193.1) | 109.8 (61.4 to 196.4) | 21.4 (18.6 to 24.7) |
| 12-17 Years, ST1: Month 30 | 86.8 (47.9 to 157.4) | 84.4 (47.2 to 150.9) | 21.5 (18.4 to 25.1) |
| 12-17 Years, ST1: Month 31 | 2125.7 (1487.7 to 3037.3) | 2040.7 (1326.0 to 3140.8) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST1: Month 39 | 135.2 (92.8 to 196.8) | 143.0 (87.4 to 234.1) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST1: Month 42 | 100.2 (69.4 to 144.5) | 89.2 (53.6 to 148.7) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST1: Month 43 | 1244.9 (839.2 to 1846.9) | 1638.9 (1037.2 to 2589.6) | 21.8 (18.2 to 26.0) |
| 12-17 Years, ST1: Month 48 | 185.1 (109.9 to 311.7) | 207.4 (120.3 to 357.6) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST2: Month 18 | 39.8 (28.2 to 56.2) | 39.3 (30.4 to 50.9) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST2: Month 19 | 1963.1 (1226.3 to 3142.5) | 3149.2 (1904.3 to 5207.9) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST2: Month 23 | 468.8 (316.7 to 694.1) | 412.2 (277.3 to 612.7) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST2: Month 26 | 241.4 (164.1 to 355.1) | 278.2 (203.5 to 380.2) | 21.1 (18.8 to 23.7) |
| 12-17 Years, ST2: Month 30 | 135.3 (73.2 to 250.1) | 169.7 (113.0 to 254.6) | 21.4 (18.6 to 24.6) |
| 12-17 Years, ST2: Month 31 | 2644.4 (1812.2 to 3858.8) | 2678.0 (1924.1 to 3727.3) | 21.6 (18.4 to 25.4) |
| 12-17 Years, ST2: Month 39 | 225.1 (151.3 to 335.1) | 265.7 (194.0 to 363.7) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST2: Month 42 | 155.8 (102.5 to 236.8) | 160.6 (102.2 to 252.4) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST2: Month 43 | 1611.9 (1055.2 to 2462.4) | 2400.5 (1558.0 to 3698.8) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST2: Month 48 | 231.7 (135.2 to 397.0) | 366.6 (227.4 to 591.1) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST3: Month 18 | 41.5 (28.3 to 61.0) | 44.8 (34.4 to 58.3) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST3: Month 19 | 2052.5 (1312.9 to 3208.6) | 2919.2 (1746.8 to 4878.4) | 21.9 (19.2 to 24.9) |
| 12-17 Years, ST3: Month 23 | 496.9 (345.7 to 714.4) | 447.1 (282.0 to 708.9) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST3: Month 26 | 237.1 (164.5 to 341.7) | 283.1 (194.3 to 412.5) | 21.3 (18.7 to 24.3) |
| 12-17 Years, ST3: Month 30 | 143.5 (77.9 to 264.5) | 167.0 (103.1 to 270.7) | 23.0 (19.6 to 26.9) |
| 12-17 Years, ST3: Month 31 | 2483.0 (1787.8 to 3448.5) | 2690.2 (1785.0 to 4054.4) | 22.5 (18.9 to 26.9) |
| 12-17 Years, ST3: Month 39 | 207.7 (142.7 to 302.3) | 253.9 (162.3 to 397.1) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST3: Month 42 | 142.1 (99.1 to 203.8) | 182.2 (115.6 to 287.1) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST3: Month 43 | 1530.5 (1046.5 to 2238.4) | 2339.8 (1523.4 to 3593.8) | 21.1 (18.8 to 23.7) |
| 12-17 Years, ST3: Month 48 | 264.8 (156.3 to 448.6) | 392.2 (237.5 to 647.7) | 21.3 (18.6 to 24.5) |
| 12-17 Years, ST4: Month 18 | 38.0 (27.7 to 52.2) | 33.6 (26.8 to 42.0) | 21.0 (19.6 to 22.5) |
| 12-17 Years, ST4: Month 19 | 1738.3 (1100.8 to 2745.2) | 2295.9 (1323.2 to 3983.7) | 22.8 (19.5 to 26.7) |
| 12-17 Years, ST4: Month 23 | 377.6 (255.6 to 557.9) | 285.3 (175.9 to 462.5) | 23.2 (19.5 to 27.6) |
| 12-17 Years, ST4: Month 26 | 169.2 (109.9 to 260.5) | 178.1 (114.5 to 277.0) | 23.4 (19.5 to 28.0) |
| 12-17 Years, ST4: Month 30 | 113.4 (64.3 to 200.0) | 112.7 (66.7 to 190.5) | 21.5 (18.4 to 25.1) |
| 12-17 Years, ST4: Month 31 | 2527.9 (1857.0 to 3441.0) | 2274.1 (1492.7 to 3464.6) | 22.6 (18.9 to 26.9) |
| 12-17 Years, ST4: Month 39 | 166.1 (108.9 to 253.3) | 180.2 (109.8 to 295.7) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST4: Month 42 | 119.4 (80.9 to 176.2) | 121.5 (75.9 to 194.4) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST4: Month 43 | 1583.8 (1088.2 to 2305.2) | 1895.2 (1210.3 to 2967.8) | 23.2 (18.5 to 29.0) |
| 12-17 Years, ST4: Month 48 | 227.3 (135.2 to 382.1) | 269.4 (164.3 to 442.0) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST5: Month 18 | 35.8 (25.5 to 50.1) | 29.5 (23.9 to 36.4) | 20.6 (19.4 to 21.9) |
| 12-17 Years, ST5: Month 19 | 1549.7 (988.0 to 2430.9) | 2065.7 (1230.6 to 3467.7) | 21.2 (18.8 to 23.7) |
| 12-17 Years, ST5: Month 23 | 334.5 (226.5 to 493.9) | 244.7 (153.9 to 389.0) | 21.3 (18.7 to 24.2) |
| 12-17 Years, ST5: Month 26 | 145.4 (89.0 to 237.5) | 160.9 (107.5 to 240.6) | 21.2 (18.8 to 23.9) |
| 12-17 Years, ST5: Month 30 | 100.5 (53.8 to 187.6) | 106.8 (63.4 to 179.8) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST5: Month 31 | 2084.9 (1527.0 to 2846.7) | 2062.9 (1375.2 to 3094.5) | 23.0 (18.8 to 28.3) |
| 12-17 Years, ST5: Month 39 | 160.1 (108.7 to 236.0) | 181.6 (124.5 to 264.8) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST5: Month 42 | 114.4 (77.0 to 169.8) | 106.1 (66.1 to 170.2) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST5: Month 43 | 1285.8 (891.4 to 1854.6) | 1802.3 (1124.4 to 2889.0) | 21.5 (18.4 to 25.2) |
| 12-17 Years, ST5: Month 48 | 191.5 (117.1 to 313.2) | 228.7 (130.2 to 401.9) | 21.5 (18.5 to 25.0) |
| 12-17 Years, ST6: Month 18 | 37.5 (26.8 to 52.3) | 31.9 (25.2 to 40.5) | 22.3 (20.1 to 24.9) |
| 12-17 Years, ST6: Month 19 | 1588.3 (1008.8 to 2500.9) | 1975.8 (1187.5 to 3287.4) | 24.4 (20.0 to 29.8) |
| 12-17 Years, ST6: Month 23 | 336.9 (215.1 to 527.7) | 237.4 (148.0 to 380.7) | 25.8 (20.1 to 33.1) |
| 12-17 Years, ST6: Month 26 | 176.2 (113.7 to 273.2) | 150.7 (97.9 to 232.0) | 22.6 (18.9 to 27.0) |
| 12-17 Years, ST6: Month 30 | 110.6 (60.2 to 203.2) | 97.2 (55.3 to 170.6) | 27.7 (20.9 to 36.8) |
| 12-17 Years, ST6: Month 31 | 2242.3 (1627.7 to 3089.0) | 1987.0 (1371.5 to 2878.8) | 25.1 (19.3 to 32.6) |
| 12-17 Years, ST6: Month 39 | 174.9 (111.7 to 273.8) | 161.4 (108.0 to 241.4) | 21.7 (18.2 to 25.9) |
| 12-17 Years, ST6: Month 42 | 131.2 (87.4 to 197.2) | 106.1 (66.3 to 169.7) | 20.0 (20.0 to 20.0) |
| 12-17 Years, ST6: Month 43 | 1318.7 (907.0 to 1917.3) | 1613.1 (1014.0 to 2566.2) | 23.3 (18.6 to 29.2) |
| 12-17 Years, ST6: Month 48 | 209.1 (125.3 to 349.0) | 235.2 (141.3 to 391.5) | 23.8 (18.5 to 30.5) |
| 18-65 Years, ST1: Month 18 | 24.6 (21.2 to 28.4) | 21.6 (20.2 to 23.2) | 21.6 (19.9 to 23.4) |
| 18-65 Years, ST1: Month 19 | 768.3 (565.5 to 1043.9) | 499.6 (356.4 to 700.4) | 21.3 (19.7 to 23.1) |
| 18-65 Years, ST1: Month 23 | 130.8 (95.7 to 178.8) | 97.8 (71.2 to 134.1) | 22.1 (19.9 to 24.5) |
| 18-65 Years, ST1: Month 26 | 72.9 (55.5 to 95.8) | 56.4 (42.6 to 74.8) | 22.8 (20.5 to 25.2) |
| 18-65 Years, ST1: Month 30 | 41.1 (33.0 to 51.3) | 41.3 (31.8 to 53.6) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST1: Month 31 | 818.5 (635.6 to 1054.0) | 606.0 (456.3 to 804.7) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST1: Month 39 | 79.9 (63.6 to 100.4) | 59.9 (44.3 to 80.8) | 20.7 (19.7 to 21.7) |
| 18-65 Years, ST1: Month 42 | 62.7 (50.4 to 77.9) | 54.7 (40.6 to 73.6) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST1: Month 43 | 791.7 (651.3 to 962.3) | 589.1 (450.7 to 770.0) | 22.0 (18.2 to 26.5) |
| 18-65 Years, ST1: Month 48 | 169.2 (126.6 to 226.1) | 138.4 (103.5 to 185.2) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST2: Month 18 | 29.5 (25.6 to 34.0) | 23.5 (21.4 to 25.9) | 20.6 (19.7 to 21.6) |
| 18-65 Years, ST2: Month 19 | 1441.7 (1128.9 to 1841.1) | 1144.1 (856.8 to 1527.8) | 20.9 (19.6 to 22.2) |
| 18-65 Years, ST2: Month 23 | 277.1 (219.6 to 349.7) | 219.3 (166.8 to 288.4) | 21.6 (19.7 to 23.6) |
| 18-65 Years, ST2: Month 26 | 134.3 (105.3 to 171.3) | 101.1 (75.9 to 134.6) | 22.2 (20.2 to 24.4) |
| 18-65 Years, ST2: Month 30 | 72.7 (56.5 to 93.5) | 70.3 (53.4 to 92.4) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST2: Month 31 | 1322.1 (1109.9 to 1575.0) | 1028.1 (818.4 to 1291.5) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST2: Month 39 | 143.2 (114.4 to 179.2) | 100.0 (72.9 to 137.0) | 20.3 (19.7 to 20.9) |
| 18-65 Years, ST2: Month 42 | 111.6 (88.3 to 141.0) | 88.8 (66.6 to 118.4) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST2: Month 43 | 1331.8 (1146.3 to 1547.4) | 975.7 (759.7 to 1253.2) | 22.0 (18.2 to 26.7) |
| 18-65 Years, ST2: Month 48 | 297.4 (231.2 to 382.5) | 234.3 (188.6 to 291.0) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST3: Month 18 | 27.0 (23.5 to 31.1) | 24.2 (22.0 to 26.6) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST3: Month 19 | 1237.2 (963.1 to 1589.4) | 948.9 (710.6 to 1267.1) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST3: Month 23 | 237.3 (178.4 to 315.6) | 200.7 (148.8 to 270.7) | 21.7 (19.5 to 24.2) |
| 18-65 Years, ST3: Month 26 | 124.6 (97.2 to 159.6) | 101.3 (75.5 to 135.9) | 22.1 (20.1 to 24.3) |
| 18-65 Years, ST3: Month 30 | 66.8 (51.9 to 86.0) | 72.6 (54.9 to 96.1) | 20.8 (19.6 to 22.1) |
| 18-65 Years, ST3: Month 31 | 1157.5 (956.5 to 1400.7) | 912.8 (702.6 to 1186.0) | 20.6 (19.5 to 21.7) |
| 18-65 Years, ST3: Month 39 | 133.1 (106.1 to 166.9) | 97.6 (71.3 to 133.5) | 20.7 (19.3 to 22.3) |
| 18-65 Years, ST3: Month 42 | 96.0 (75.9 to 121.4) | 88.9 (66.6 to 118.5) | 20.6 (19.4 to 22.0) |
| 18-65 Years, ST3: Month 43 | 1104.0 (925.1 to 1317.4) | 820.3 (627.5 to 1072.4) | 22.0 (18.2 to 26.6) |
| 18-65 Years, ST3: Month 48 | 279.3 (212.3 to 367.3) | 232.1 (178.2 to 302.3) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST4: Month 18 | 26.8 (23.4 to 30.8) | 22.3 (20.5 to 24.3) | 21.5 (19.9 to 23.3) |
| 18-65 Years, ST4: Month 19 | 994.2 (762.2 to 1296.8) | 668.9 (487.6 to 917.5) | 21.2 (19.6 to 23.0) |
| 18-65 Years, ST4: Month 23 | 159.1 (118.9 to 212.9) | 121.5 (90.0 to 164.1) | 22.5 (19.9 to 25.5) |
| 18-65 Years, ST4: Month 26 | 95.6 (75.3 to 121.4) | 67.8 (51.0 to 90.1) | 23.6 (20.9 to 26.6) |
| 18-65 Years, ST4: Month 30 | 55.5 (44.4 to 69.3) | 47.1 (36.4 to 60.9) | 21.5 (19.4 to 23.9) |
| 18-65 Years, ST4: Month 31 | 1058.7 (866.2 to 1294.1) | 747.9 (570.9 to 979.8) | 22.3 (19.7 to 25.4) |
| 18-65 Years, ST4: Month 39 | 106.0 (84.3 to 133.1) | 79.3 (59.3 to 106.0) | 21.6 (19.4 to 24.1) |
| 18-65 Years, ST4: Month 42 | 82.3 (65.6 to 103.4) | 72.3 (53.6 to 97.5) | 22.0 (19.6 to 24.7) |
| 18-65 Years, ST4: Month 43 | 1051.5 (882.2 to 1253.2) | 754.6 (585.5 to 972.5) | 23.2 (18.9 to 28.4) |
| 18-65 Years, ST4: Month 48 | 223.0 (169.9 to 292.7) | 176.3 (139.2 to 223.3) | 21.0 (19.0 to 23.1) |
| 18-65 Years, ST5: Month 18 | 24.2 (21.4 to 27.4) | 21.7 (20.3 to 23.1) | 20.2 (19.8 to 20.5) |
| 18-65 Years, ST5: Month 19 | 930.5 (702.6 to 1232.3) | 637.0 (460.8 to 880.6) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST5: Month 23 | 164.9 (126.3 to 215.4) | 105.8 (76.3 to 146.8) | 21.3 (19.5 to 23.3) |
| 18-65 Years, ST5: Month 26 | 95.1 (75.0 to 120.6) | 62.6 (46.9 to 83.6) | 22.4 (20.3 to 24.7) |
| 18-65 Years, ST5: Month 30 | 47.7 (37.4 to 60.8) | 48.3 (37.1 to 63.0) | 20.5 (19.5 to 21.6) |
| 18-65 Years, ST5: Month 31 | 974.1 (797.9 to 1189.3) | 696.3 (546.3 to 887.5) | 20.6 (19.4 to 22.0) |
| 18-65 Years, ST5: Month 39 | 102.2 (82.5 to 126.7) | 70.9 (53.0 to 95.0) | 20.9 (19.6 to 22.3) |
| 18-65 Years, ST5: Month 42 | 72.3 (57.6 to 90.9) | 69.9 (53.3 to 91.8) | 20.5 (19.5 to 21.4) |
| 18-65 Years, ST5: Month 43 | 937.6 (789.8 to 1113.1) | 688.1 (540.9 to 875.3) | 22.0 (18.2 to 26.7) |
| 18-65 Years, ST5: Month 48 | 194.9 (146.5 to 259.3) | 142.0 (104.3 to 193.4) | 20.0 (20.0 to 20.0) |
| 18-65 Years, ST6: Month 18 | 26.5 (23.0 to 30.6) | 21.8 (20.3 to 23.3) | 21.1 (20.0 to 22.3) |
| 18-65 Years, ST6: Month 19 | 913.7 (700.2 to 1192.2) | 621.8 (447.7 to 863.8) | 21.3 (20.0 to 22.7) |
| 18-65 Years, ST6: Month 23 | 166.9 (126.6 to 220.0) | 123.7 (92.5 to 165.4) | 21.5 (19.6 to 23.6) |
| 18-65 Years, ST6: Month 26 | 99.8 (77.7 to 128.2) | 65.9 (49.9 to 87.2) | 23.2 (20.9 to 25.7) |
| 18-65 Years, ST6: Month 30 | 52.0 (40.3 to 67.0) | 50.2 (38.9 to 64.7) | 21.0 (19.6 to 22.4) |
| 18-65 Years, ST6: Month 31 | 962.8 (791.1 to 1171.8) | 679.3 (531.4 to 868.5) | 21.1 (19.5 to 22.9) |
| 18-65 Years, ST6: Month 39 | 100.9 (79.2 to 128.6) | 71.2 (52.9 to 95.9) | 21.6 (19.6 to 23.7) |
| 18-65 Years, ST6: Month 42 | 80.2 (62.8 to 102.4) | 68.3 (51.1 to 91.4) | 20.8 (19.3 to 22.4) |
| 18-65 Years, ST6: Month 43 | 939.6 (785.9 to 1123.3) | 676.9 (526.3 to 870.5) | 22.7 (18.7 to 27.5) |
| 18-65 Years, ST6: Month 48 | 210.1 (155.5 to 283.8) | 161.2 (124.7 to 208.5) | 20.4 (19.6 to 21.3) |
Seroconversion for ELISA was defined as a change from seronegative at baseline to seropositive at a measured time point. For participants who were OspA seropositive at baseline, seroconversion was defined as a \>=4-fold rise in IgG antibody titer from baseline. SCR was percentage of participants with seroconversion reported for each OspA serotype specific IgG ST1 to ST6, as determined by ELISA.
| Percentage of participants | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| 5-11 Years, ST1: Month 18 | 20.0 (10.0 to 35.9) | 8.8 (3.0 to 23.0) | 0.0 (0.0 to 9.4) |
| 5-11 Years, ST1: Month 19 | 96.3 (81.7 to 99.3) | 90.0 (69.9 to 97.2) | 0.0 (0.0 to 11.4) |
| 5-11 Years, ST1: Month 23 | 89.3 (72.8 to 96.3) | 81.8 (61.5 to 92.7) | 0.0 (0.0 to 12.1) |
| 5-11 Years, ST1: Month 26 | 87.0 (67.9 to 95.5) | 70.6 (46.9 to 86.7) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST1: Month 30 | 76.9 (57.9 to 89.0) | 52.4 (32.4 to 71.7) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST1: Month 31 | 96.3 (81.7 to 99.3) | 90.9 (72.2 to 97.5) | 4.3 (0.8 to 21.0) |
| 5-11 Years, ST1: Month 39 | 84.0 (65.3 to 93.6) | 90.9 (62.3 to 98.4) | 5.0 (0.9 to 23.6) |
| 5-11 Years, ST1: Month 42 | 85.7 (65.4 to 95.0) | 92.3 (66.7 to 98.6) | 11.8 (3.3 to 34.3) |
| 5-11 Years, ST1: Month 43 | 100 (87.1 to 100) | 100 (81.6 to 100) | 0.0 (0.0 to 17.6) |
| 5-11 Years, ST1: Month 48 | 100 (83.9 to 100) | 92.9 (68.5 to 98.7) | 0.0 (0.0 to 20.4) |
| 5-11 Years, ST2: Month 18 | 57.1 (40.9 to 72.0) | 50.0 (34.1 to 65.9) | 0.0 (0.0 to 9.4) |
| 5-11 Years, ST2: Month 19 | 96.3 (81.7 to 99.3) | 90.0 (69.9 to 97.2) | 0.0 (0.0 to 11.4) |
| 5-11 Years, ST2: Month 23 | 96.4 (82.3 to 99.4) | 90.9 (72.2 to 97.5) | 0.0 (0.0 to 12.1) |
| 5-11 Years, ST2: Month 26 | 100 (85.7 to 100) | 82.4 (59.0 to 93.8) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST2: Month 30 | 100 (87.1 to 100) | 76.2 (54.9 to 89.4) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST2: Month 31 | 96.3 (81.7 to 99.3) | 95.5 (78.2 to 99.2) | 4.3 (0.8 to 21.0) |
| 5-11 Years, ST2: Month 39 | 92.0 (75.0 to 97.8) | 100 (74.1 to 100) | 5.0 (0.9 to 23.6) |
| 5-11 Years, ST2: Month 42 | 90.5 (71.1 to 97.3) | 100 (77.2 to 100) | 5.9 (1.0 to 27.0) |
| 5-11 Years, ST2: Month 43 | 100 (87.1 to 100) | 100 (81.6 to 100) | 0.0 (0.0 to 17.6) |
| 5-11 Years, ST2: Month 48 | 100 (83.9 to 100) | 100 (78.5 to 100) | 0.0 (0.0 to 20.4) |
| 5-11 Years, ST3: Month 18 | 54.3 (38.2 to 69.5) | 70.6 (53.8 to 83.2) | 2.7 (0.5 to 13.8) |
| 5-11 Years, ST3: Month 19 | 96.3 (81.7 to 99.3) | 90.0 (69.9 to 97.2) | 6.7 (1.8 to 21.3) |
| 5-11 Years, ST3: Month 23 | 96.4 (82.3 to 99.4) | 95.5 (78.2 to 99.2) | 0.0 (0.0 to 12.1) |
| 5-11 Years, ST3: Month 26 | 95.7 (79.0 to 99.2) | 94.1 (73.0 to 99.0) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST3: Month 30 | 84.6 (66.5 to 93.8) | 85.7 (65.4 to 95.0) | 4.2 (0.7 to 20.2) |
| 5-11 Years, ST3: Month 31 | 96.3 (81.7 to 99.3) | 95.5 (78.2 to 99.2) | 4.3 (0.8 to 21.0) |
| 5-11 Years, ST3: Month 39 | 88.0 (70.0 to 95.8) | 100 (74.1 to 100) | 5.0 (0.9 to 23.6) |
| 5-11 Years, ST3: Month 42 | 95.2 (77.3 to 99.2) | 100 (77.2 to 100) | 5.9 (1.0 to 27.0) |
| 5-11 Years, ST3: Month 43 | 100 (87.1 to 100) | 100 (81.6 to 100) | 5.6 (1.0 to 25.8) |
| 5-11 Years, ST3: Month 48 | 100 (83.9 to 100) | 100 (78.5 to 100) | 6.7 (1.2 to 29.8) |
| 5-11 Years, ST4: Month 18 | 48.6 (33.0 to 64.4) | 29.4 (16.8 to 46.2) | 0.0 (0.0 to 9.4) |
| 5-11 Years, ST4: Month 19 | 96.3 (81.7 to 99.3) | 90.0 (69.9 to 97.2) | 3.3 (0.6 to 16.7) |
| 5-11 Years, ST4: Month 23 | 96.4 (82.3 to 99.4) | 90.9 (72.2 to 97.5) | 0.0 (0.0 to 12.1) |
| 5-11 Years, ST4: Month 26 | 95.7 (79.0 to 99.2) | 76.5 (52.7 to 90.4) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST4: Month 30 | 84.6 (66.5 to 93.8) | 71.4 (50.0 to 86.2) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST4: Month 31 | 96.3 (81.7 to 99.3) | 90.9 (72.2 to 97.5) | 4.3 (0.8 to 21.0) |
| 5-11 Years, ST4: Month 39 | 84.0 (65.3 to 93.6) | 100 (74.1 to 100) | 5.0 (0.9 to 23.6) |
| 5-11 Years, ST4: Month 42 | 95.2 (77.3 to 99.2) | 84.6 (57.8 to 95.7) | 11.8 (3.3 to 34.3) |
| 5-11 Years, ST4: Month 43 | 100 (87.1 to 100) | 100 (81.6 to 100) | 0.0 (0.0 to 17.6) |
| 5-11 Years, ST4: Month 48 | 100 (83.9 to 100) | 100 (78.5 to 100) | 0.0 (0.0 to 20.4) |
| 5-11 Years, ST5: Month 18 | 42.9 (28.0 to 59.1) | 29.4 (16.8 to 46.2) | 0.0 (0.0 to 9.4) |
| 5-11 Years, ST5: Month 19 | 96.3 (81.7 to 99.3) | 90.0 (69.9 to 97.2) | 0.0 (0.0 to 11.4) |
| 5-11 Years, ST5: Month 23 | 92.9 (77.4 to 98.0) | 81.8 (61.5 to 92.7) | 0.0 (0.0 to 12.1) |
| 5-11 Years, ST5: Month 26 | 100 (85.7 to 100) | 76.5 (52.7 to 90.4) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST5: Month 30 | 88.5 (71.0 to 96.0) | 76.2 (54.9 to 89.4) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST5: Month 31 | 96.3 (81.7 to 99.3) | 95.5 (78.2 to 99.2) | 4.3 (0.8 to 21.0) |
| 5-11 Years, ST5: Month 39 | 84.0 (65.3 to 93.6) | 100 (74.1 to 100) | 5.0 (0.9 to 23.6) |
| 5-11 Years, ST5: Month 42 | 95.2 (77.3 to 99.2) | 92.3 (66.7 to 98.6) | 0.0 (0.0 to 18.4) |
| 5-11 Years, ST5: Month 43 | 100 (87.1 to 100) | 100 (81.6 to 100) | 0.0 (0.0 to 17.6) |
| 5-11 Years, ST5: Month 48 | 100 (83.9 to 100) | 92.9 (68.5 to 98.7) | 0.0 (0.0 to 20.4) |
| 5-11 Years, ST6: Month 18 | 27.8 (15.8 to 44.0) | 32.4 (19.1 to 49.2) | 0.0 (0.0 to 9.4) |
| 5-11 Years, ST6: Month 19 | 92.9 (77.4 to 98.0) | 90.0 (69.9 to 97.2) | 6.7 (1.8 to 21.3) |
| 5-11 Years, ST6: Month 23 | 92.9 (77.4 to 98.0) | 81.8 (61.5 to 92.7) | 0.0 (0.0 to 12.1) |
| 5-11 Years, ST6: Month 26 | 95.7 (79.0 to 99.2) | 76.5 (52.7 to 90.4) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST6: Month 30 | 76.9 (57.9 to 89.0) | 81.0 (60.0 to 92.3) | 0.0 (0.0 to 13.8) |
| 5-11 Years, ST6: Month 31 | 96.3 (81.7 to 99.3) | 90.9 (72.2 to 97.5) | 4.3 (0.8 to 21.0) |
| 5-11 Years, ST6: Month 39 | 92.0 (75.0 to 97.8) | 100 (74.1 to 100) | 5.0 (0.9 to 23.6) |
| 5-11 Years, ST6: Month 42 | 90.5 (71.1 to 97.3) | 76.9 (49.7 to 91.8) | 5.9 (1.0 to 27.0) |
| 5-11 Years, ST6: Month 43 | 100 (87.1 to 100) | 100 (81.6 to 100) | 5.6 (1.0 to 25.8) |
| 5-11 Years, ST6: Month 48 | 100 (83.9 to 100) | 92.9 (68.5 to 98.7) | 0.0 (0.0 to 20.4) |
| 12-17 Years, ST1: Month 18 | 27.8 (15.8 to 44.0) | 16.2 (7.7 to 31.1) | 0.0 (0.0 to 10.2) |
| 12-17 Years, ST1: Month 19 | 96.3 (81.7 to 99.3) | 96.2 (81.1 to 99.3) | 0.0 (0.0 to 12.9) |
| 12-17 Years, ST1: Month 23 | 100 (86.7 to 100) | 92.6 (76.6 to 97.9) | 0.0 (0.0 to 15.5) |
| 12-17 Years, ST1: Month 26 | 83.3 (64.1 to 93.3) | 68.0 (48.4 to 82.8) | 0.0 (0.0 to 15.5) |
| 12-17 Years, ST1: Month 30 | 71.4 (50.0 to 86.2) | 66.7 (45.4 to 82.8) | 0.0 (0.0 to 16.8) |
| 12-17 Years, ST1: Month 31 | 100 (83.9 to 100) | 100 (84.5 to 100) | 0.0 (0.0 to 15.5) |
| 12-17 Years, ST1: Month 39 | 95.2 (77.3 to 99.2) | 87.0 (67.9 to 95.5) | 0.0 (0.0 to 22.8) |
| 12-17 Years, ST1: Month 42 | 87.0 (67.9 to 95.5) | 75.0 (53.1 to 88.8) | 0.0 (0.0 to 20.4) |
| 12-17 Years, ST1: Month 43 | 100 (85.7 to 100) | 100 (84.5 to 100) | 6.3 (1.1 to 28.3) |
| 12-17 Years, ST1: Month 48 | 90.0 (69.9 to 97.2) | 94.7 (75.4 to 99.1) | 0.0 (0.0 to 18.4) |
| 12-17 Years, ST2: Month 18 | 41.7 (27.1 to 57.8) | 48.6 (33.4 to 64.1) | 0.0 (0.0 to 10.2) |
| 12-17 Years, ST2: Month 19 | 96.3 (81.7 to 99.3) | 96.2 (81.1 to 99.3) | 0.0 (0.0 to 12.9) |
| 12-17 Years, ST2: Month 23 | 100 (86.7 to 100) | 96.3 (81.7 to 99.3) | 0.0 (0.0 to 15.5) |
| 12-17 Years, ST2: Month 26 | 100 (86.2 to 100) | 100 (86.7 to 100) | 4.8 (0.8 to 22.7) |
| 12-17 Years, ST2: Month 30 | 81.0 (60.0 to 92.3) | 95.2 (77.3 to 99.2) | 5.3 (0.9 to 24.6) |
| 12-17 Years, ST2: Month 31 | 100 (83.9 to 100) | 100 (84.5 to 100) | 4.8 (0.8 to 22.7) |
| 12-17 Years, ST2: Month 39 | 100 (84.5 to 100) | 100 (85.7 to 100) | 0.0 (0.0 to 22.8) |
| 12-17 Years, ST2: Month 42 | 91.3 (73.2 to 97.6) | 90.0 (69.9 to 97.2) | 0.0 (0.0 to 20.4) |
| 12-17 Years, ST2: Month 43 | 100 (85.7 to 100) | 100 (84.5 to 100) | 0.0 (0.0 to 19.4) |
| 12-17 Years, ST2: Month 48 | 90.0 (69.9 to 97.2) | 94.7 (75.4 to 99.1) | 0.0 (0.0 to 18.4) |
| 12-17 Years, ST3: Month 18 | 38.9 (24.8 to 55.1) | 54.1 (38.4 to 69.0) | 0.0 (0.0 to 10.2) |
| 12-17 Years, ST3: Month 19 | 96.3 (81.7 to 99.3) | 96.2 (81.1 to 99.3) | 3.8 (0.7 to 18.9) |
| 12-17 Years, ST3: Month 23 | 100 (86.7 to 100) | 96.3 (81.7 to 99.3) | 0.0 (0.0 to 15.5) |
| 12-17 Years, ST3: Month 26 | 100 (86.2 to 100) | 100 (86.7 to 100) | 4.8 (0.8 to 22.7) |
| 12-17 Years, ST3: Month 30 | 85.7 (65.4 to 95.0) | 95.2 (77.3 to 99.2) | 15.8 (5.5 to 37.6) |
| 12-17 Years, ST3: Month 31 | 100 (83.9 to 100) | 100 (84.5 to 100) | 9.5 (2.7 to 28.9) |
| 12-17 Years, ST3: Month 39 | 100 (84.5 to 100) | 95.7 (79.0 to 99.2) | 0.0 (0.0 to 22.8) |
| 12-17 Years, ST3: Month 42 | 95.7 (79.0 to 99.2) | 95.0 (76.4 to 99.1) | 0.0 (0.0 to 20.4) |
| 12-17 Years, ST3: Month 43 | 100 (85.7 to 100) | 100 (84.5 to 100) | 6.3 (1.1 to 28.3) |
| 12-17 Years, ST3: Month 48 | 90.0 (69.9 to 97.2) | 94.7 (75.4 to 99.1) | 5.9 (1.0 to 27.0) |
| 12-17 Years, ST4: Month 18 | 44.4 (29.5 to 60.4) | 29.7 (17.5 to 45.8) | 0.0 (0.0 to 10.2) |
| 12-17 Years, ST4: Month 19 | 96.3 (81.7 to 99.3) | 96.2 (81.1 to 99.3) | 3.8 (0.7 to 18.9) |
| 12-17 Years, ST4: Month 23 | 100 (86.7 to 100) | 96.3 (81.7 to 99.3) | 4.8 (0.8 to 22.7) |
| 12-17 Years, ST4: Month 26 | 91.7 (74.2 to 97.7) | 92.0 (75.0 to 97.8) | 4.8 (0.8 to 22.7) |
| 12-17 Years, ST4: Month 30 | 81.0 (60.0 to 92.3) | 71.4 (50.0 to 86.2) | 0.0 (0.0 to 16.8) |
| 12-17 Years, ST4: Month 31 | 100 (83.9 to 100) | 100 (84.5 to 100) | 0.0 (0.0 to 15.5) |
| 12-17 Years, ST4: Month 39 | 90.5 (71.1 to 97.3) | 87.0 (67.9 to 95.5) | 0.0 (0.0 to 22.8) |
| 12-17 Years, ST4: Month 42 | 87.0 (67.9 to 95.5) | 80.0 (58.4 to 91.9) | 0.0 (0.0 to 20.4) |
| 12-17 Years, ST4: Month 43 | 100 (85.7 to 100) | 100 (84.5 to 100) | 12.5 (3.5 to 36.0) |
| 12-17 Years, ST4: Month 48 | 90.0 (69.9 to 97.2) | 94.7 (75.4 to 99.1) | 0.0 (0.0 to 18.4) |
| 12-17 Years, ST5: Month 18 | 33.3 (20.2 to 49.7) | 24.3 (13.4 to 40.1) | 2.9 (0.5 to 14.9) |
| 12-17 Years, ST5: Month 19 | 96.3 (81.7 to 99.3) | 96.2 (81.1 to 99.3) | 3.8 (0.7 to 18.9) |
| 12-17 Years, ST5: Month 23 | 100 (86.7 to 100) | 92.6 (76.6 to 97.9) | 4.8 (0.8 to 22.7) |
| 12-17 Years, ST5: Month 26 | 83.3 (64.1 to 93.3) | 92.0 (75.0 to 97.8) | 4.8 (0.8 to 22.7) |
| 12-17 Years, ST5: Month 30 | 66.7 (45.4 to 82.8) | 76.2 (54.9 to 89.4) | 0.0 (0.0 to 16.8) |
| 12-17 Years, ST5: Month 31 | 100 (83.9 to 100) | 100 (84.5 to 100) | 9.5 (2.7 to 28.9) |
| 12-17 Years, ST5: Month 39 | 95.2 (77.3 to 99.2) | 100 (85.7 to 100) | 0.0 (0.0 to 22.8) |
| 12-17 Years, ST5: Month 42 | 87.0 (67.9 to 95.5) | 80.0 (58.4 to 91.9) | 0.0 (0.0 to 20.4) |
| 12-17 Years, ST5: Month 43 | 100 (85.7 to 100) | 100 (84.5 to 100) | 6.3 (1.1 to 28.3) |
| 12-17 Years, ST5: Month 48 | 90.0 (69.9 to 97.2) | 89.5 (68.6 to 97.1) | 5.9 (1.0 to 27.0) |
| 12-17 Years, ST6: Month 18 | 33.3 (20.2 to 49.7) | 21.6 (11.4 to 37.2) | 2.9 (0.5 to 14.9) |
| 12-17 Years, ST6: Month 19 | 96.3 (81.7 to 99.3) | 96.2 (81.1 to 99.3) | 0.0 (0.0 to 12.9) |
| 12-17 Years, ST6: Month 23 | 96.0 (80.5 to 99.3) | 88.9 (71.9 to 96.1) | 0.0 (0.0 to 15.5) |
| 12-17 Years, ST6: Month 26 | 95.8 (79.8 to 99.3) | 80.0 (60.9 to 91.1) | 0.0 (0.0 to 15.5) |
| 12-17 Years, ST6: Month 30 | 66.7 (45.4 to 82.8) | 61.9 (40.9 to 79.2) | 10.5 (2.9 to 31.4) |
| 12-17 Years, ST6: Month 31 | 100 (83.9 to 100) | 100 (84.5 to 100) | 0.0 (0.0 to 15.5) |
| 12-17 Years, ST6: Month 39 | 95.2 (77.3 to 99.2) | 91.3 (73.2 to 97.6) | 0.0 (0.0 to 22.8) |
| 12-17 Years, ST6: Month 42 | 87.0 (67.9 to 95.5) | 80.0 (58.4 to 91.9) | 0.0 (0.0 to 20.4) |
| 12-17 Years, ST6: Month 43 | 100 (85.7 to 100) | 100 (84.5 to 100) | 0.0 (0.0 to 19.4) |
| 12-17 Years, ST6: Month 48 | 85.0 (64.0 to 94.8) | 89.5 (68.6 to 97.1) | 0.0 (0.0 to 18.4) |
| 18-65 Years, ST1: Month 18 | 10.5 (5.6 to 18.7) | 6.8 (3.0 to 15.1) | 0.0 (0.0 to 4.3) |
| 18-65 Years, ST1: Month 19 | 97.2 (90.4 to 99.2) | 95.4 (87.3 to 98.4) | 0.0 (0.0 to 5.4) |
| 18-65 Years, ST1: Month 23 | 82.3 (71.0 to 89.8) | 75.0 (62.8 to 84.2) | 2.9 (0.8 to 10.0) |
| 18-65 Years, ST1: Month 26 | 68.3 (56.0 to 78.4) | 57.4 (44.9 to 69.0) | 6.0 (2.3 to 14.4) |
| 18-65 Years, ST1: Month 30 | 45.0 (33.1 to 57.5) | 41.8 (29.7 to 55.0) | 0.0 (0.0 to 6.6) |
| 18-65 Years, ST1: Month 31 | 97.0 (89.6 to 99.2) | 100 (93.5 to 100) | 0.0 (0.0 to 6.8) |
| 18-65 Years, ST1: Month 39 | 73.8 (61.6 to 83.2) | 59.2 (45.2 to 71.8) | 1.9 (0.3 to 9.9) |
| 18-65 Years, ST1: Month 42 | 70.5 (58.1 to 80.4) | 57.1 (43.3 to 70.0) | 0.0 (0.0 to 6.8) |
| 18-65 Years, ST1: Month 43 | 100 (94.3 to 100) | 98.1 (90.1 to 99.7) | 1.9 (0.3 to 9.8) |
| 18-65 Years, ST1: Month 48 | 90.4 (79.4 to 95.8) | 93.5 (82.5 to 97.8) | 0.0 (0.0 to 8.2) |
| 18-65 Years, ST2: Month 18 | 25.6 (17.5 to 35.7) | 13.7 (7.6 to 23.4) | 0.0 (0.0 to 4.3) |
| 18-65 Years, ST2: Month 19 | 98.6 (92.5 to 99.8) | 98.5 (91.8 to 99.7) | 0.0 (0.0 to 5.4) |
| 18-65 Years, ST2: Month 23 | 95.2 (86.7 to 98.3) | 91.7 (81.9 to 96.4) | 1.4 (0.3 to 7.8) |
| 18-65 Years, ST2: Month 26 | 85.7 (75.0 to 92.3) | 73.8 (61.6 to 83.2) | 6.0 (2.3 to 14.4) |
| 18-65 Years, ST2: Month 30 | 68.3 (55.8 to 78.7) | 65.5 (52.3 to 76.6) | 0.0 (0.0 to 6.6) |
| 18-65 Years, ST2: Month 31 | 100 (94.5 to 100) | 100 (93.5 to 100) | 0.0 (0.0 to 6.8) |
| 18-65 Years, ST2: Month 39 | 86.9 (76.2 to 93.2) | 73.5 (59.7 to 83.8) | 1.9 (0.3 to 9.9) |
| 18-65 Years, ST2: Month 42 | 82.0 (70.5 to 89.6) | 73.5 (59.7 to 83.8) | 0.0 (0.0 to 6.8) |
| 18-65 Years, ST2: Month 43 | 100 (94.3 to 100) | 98.1 (90.1 to 99.7) | 1.9 (0.3 to 9.8) |
| 18-65 Years, ST2: Month 48 | 94.2 (84.4 to 98.0) | 97.8 (88.7 to 99.6) | 0.0 (0.0 to 8.2) |
| 18-65 Years, ST3: Month 18 | 18.6 (11.8 to 28.1) | 19.2 (11.8 to 29.7) | 0.0 (0.0 to 4.3) |
| 18-65 Years, ST3: Month 19 | 98.6 (92.5 to 99.8) | 98.5 (91.8 to 99.7) | 0.0 (0.0 to 5.4) |
| 18-65 Years, ST3: Month 23 | 88.7 (78.5 to 94.4) | 88.3 (77.8 to 94.2) | 2.9 (0.8 to 10.0) |
| 18-65 Years, ST3: Month 26 | 84.1 (73.2 to 91.1) | 77.0 (65.1 to 85.8) | 7.5 (3.2 to 16.3) |
| 18-65 Years, ST3: Month 30 | 66.7 (54.1 to 77.3) | 69.1 (56.0 to 79.7) | 3.7 (1.0 to 12.5) |
| 18-65 Years, ST3: Month 31 | 100 (94.5 to 100) | 100 (93.5 to 100) | 1.9 (0.3 to 9.9) |
| 18-65 Years, ST3: Month 39 | 88.5 (78.2 to 94.3) | 75.5 (61.9 to 85.4) | 1.9 (0.3 to 9.9) |
| 18-65 Years, ST3: Month 42 | 83.6 (72.4 to 90.8) | 79.6 (66.4 to 88.5) | 1.9 (0.3 to 9.9) |
| 18-65 Years, ST3: Month 43 | 100 (94.3 to 100) | 98.1 (90.1 to 99.7) | 1.9 (0.3 to 9.8) |
| 18-65 Years, ST3: Month 48 | 96.2 (87.0 to 98.9) | 95.7 (85.5 to 98.8) | 0.0 (0.0 to 8.2) |
| 18-65 Years, ST4: Month 18 | 18.6 (11.8 to 28.1) | 9.6 (4.7 to 18.5) | 2.4 (0.6 to 8.2) |
| 18-65 Years, ST4: Month 19 | 98.6 (92.5 to 99.8) | 95.4 (87.3 to 98.4) | 3.0 (0.8 to 10.2) |
| 18-65 Years, ST4: Month 23 | 85.5 (74.7 to 92.2) | 83.3 (72.0 to 90.7) | 2.9 (0.8 to 10.0) |
| 18-65 Years, ST4: Month 26 | 81.0 (69.6 to 88.8) | 63.9 (51.4 to 74.8) | 10.4 (5.2 to 20.0) |
| 18-65 Years, ST4: Month 30 | 65.0 (52.4 to 75.8) | 52.7 (39.8 to 65.3) | 1.9 (0.3 to 9.8) |
| 18-65 Years, ST4: Month 31 | 100 (94.5 to 100) | 100 (93.5 to 100) | 3.8 (1.0 to 12.8) |
| 18-65 Years, ST4: Month 39 | 83.6 (72.4 to 90.8) | 73.5 (59.7 to 83.8) | 1.9 (0.3 to 9.9) |
| 18-65 Years, ST4: Month 42 | 77.0 (65.1 to 85.8) | 69.4 (55.5 to 80.5) | 3.8 (1.0 to 12.8) |
| 18-65 Years, ST4: Month 43 | 100 (94.3 to 100) | 98.1 (90.1 to 99.7) | 3.7 (1.0 to 12.5) |
| 18-65 Years, ST4: Month 48 | 94.2 (84.4 to 98.0) | 100 (92.3 to 100) | 0.0 (0.0 to 8.2) |
| 18-65 Years, ST5: Month 18 | 11.6 (6.4 to 20.1) | 8.2 (3.8 to 16.8) | 1.2 (0.2 to 6.4) |
| 18-65 Years, ST5: Month 19 | 97.2 (90.4 to 99.2) | 95.4 (87.3 to 98.4) | 0.0 (0.0 to 5.4) |
| 18-65 Years, ST5: Month 23 | 87.1 (76.6 to 93.3) | 70.0 (57.5 to 80.1) | 2.9 (0.8 to 10.0) |
| 18-65 Years, ST5: Month 26 | 81.0 (69.6 to 88.8) | 55.7 (43.3 to 67.5) | 7.5 (3.2 to 16.3) |
| 18-65 Years, ST5: Month 30 | 48.3 (36.2 to 60.7) | 49.1 (36.4 to 61.9) | 1.9 (0.3 to 9.8) |
| 18-65 Years, ST5: Month 31 | 100 (94.5 to 100) | 100 (93.5 to 100) | 1.9 (0.3 to 9.9) |
| 18-65 Years, ST5: Month 39 | 83.6 (72.4 to 90.8) | 67.3 (53.4 to 78.8) | 3.8 (1.0 to 12.8) |
| 18-65 Years, ST5: Month 42 | 72.1 (59.8 to 81.8) | 75.5 (61.9 to 85.4) | 1.9 (0.3 to 9.9) |
| 18-65 Years, ST5: Month 43 | 100 (94.3 to 100) | 98.1 (90.1 to 99.7) | 1.9 (0.3 to 9.8) |
| 18-65 Years, ST5: Month 48 | 90.4 (79.4 to 95.8) | 84.8 (71.8 to 92.4) | 0.0 (0.0 to 8.2) |
| 18-65 Years, ST6: Month 18 | 15.1 (9.1 to 24.2) | 6.8 (3.0 to 15.1) | 3.5 (1.2 to 9.9) |
| 18-65 Years, ST6: Month 19 | 98.6 (92.5 to 99.8) | 95.4 (87.3 to 98.4) | 4.5 (1.5 to 12.4) |
| 18-65 Years, ST6: Month 23 | 87.1 (76.6 to 93.3) | 81.7 (70.1 to 89.4) | 4.3 (1.5 to 12.0) |
| 18-65 Years, ST6: Month 26 | 79.4 (67.8 to 87.5) | 57.4 (44.9 to 69.0) | 11.9 (6.2 to 21.8) |
| 18-65 Years, ST6: Month 30 | 50.0 (37.7 to 62.3) | 50.9 (38.1 to 63.6) | 3.7 (1.0 to 12.5) |
| 18-65 Years, ST6: Month 31 | 100 (94.5 to 100) | 100 (93.5 to 100) | 3.8 (1.0 to 12.8) |
| 18-65 Years, ST6: Month 39 | 78.7 (66.9 to 87.1) | 65.3 (51.3 to 77.1) | 5.7 (1.9 to 15.4) |
| 18-65 Years, ST6: Month 42 | 72.1 (59.8 to 81.8) | 65.3 (51.3 to 77.1) | 1.9 (0.3 to 9.9) |
| 18-65 Years, ST6: Month 43 | 100 (94.3 to 100) | 98.1 (90.1 to 99.7) | 3.7 (1.0 to 12.5) |
| 18-65 Years, ST6: Month 48 | 92.3 (81.8 to 97.0) | 95.7 (85.5 to 98.8) | 2.3 (0.4 to 12.1) |
GMFRs for IgG were determined by IgG binding assay for each OspA serotype (ST1-ST6), stratified by age group (5-11, 12-17 and 18-65 years) at Months 19, 31, and 43 relative to the corresponding pre-booster timepoints Months 18, 30, and 42, respectively.
| Fold rise | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo |
|---|---|---|---|
| 5-11 Years, ST1: Month 19 | 54.0 (35.4 to 82.5) | 58.7 (27.2 to 126.5) | 1.0 (1.0 to 1.0) |
| 5-11 Years, ST1: Month 31 | 17.4 (8.1 to 37.4) | 23.0 (10.3 to 51.3) | 1.2 (0.8 to 2.0) |
| 5-11 Years, ST1: Month 43 | 16.5 (11.6 to 23.3) | 24.3 (14.6 to 40.7) | 0.9 (0.7 to 1.1) |
| 5-11 Years, ST2: Month 19 | 63.1 (39.7 to 100.3) | 49.0 (20.7 to 115.7) | 1.0 (1.0 to 1.0) |
| 5-11 Years, ST2: Month 31 | 13.4 (6.7 to 27.1) | 18.9 (9.2 to 39.2) | 1.3 (0.8 to 2.0) |
| 5-11 Years, ST2: Month 43 | 14.3 (9.8 to 20.8) | 20.4 (11.6 to 35.8) | 0.9 (0.7 to 1.2) |
| 5-11 Years, ST3: Month 19 | 53.8 (33.9 to 85.4) | 37.4 (17.0 to 82.7) | 1.1 (1.0 to 1.2) |
| 5-11 Years, ST3: Month 31 | 14.6 (7.1 to 30.4) | 14.4 (6.7 to 30.9) | 1.2 (0.7 to 2.0) |
| 5-11 Years, ST3: Month 43 | 12.6 (8.6 to 18.4) | 20.1 (11.3 to 35.8) | 1.0 (0.8 to 1.3) |
| 5-11 Years, ST4: Month 19 | 49.8 (30.6 to 81.1) | 59.6 (26.6 to 133.7) | 1.1 (1.0 to 1.2) |
| 5-11 Years, ST4: Month 31 | 16.2 (7.8 to 33.7) | 21.0 (10.2 to 43.1) | 1.2 (0.8 to 2.0) |
| 5-11 Years, ST4: Month 43 | 13.2 (9.2 to 19.0) | 26.0 (15.0 to 45.3) | 0.9 (0.7 to 1.1) |
| 5-11 Years, ST5: Month 19 | 57.1 (36.2 to 90.3) | 54.0 (24.9 to 117.3) | 1.0 (1.0 to 1.0) |
| 5-11 Years, ST5: Month 31 | 15.3 (7.4 to 31.7) | 17.4 (8.6 to 35.0) | 1.3 (0.8 to 2.1) |
| 5-11 Years, ST5: Month 43 | 13.8 (10.1 to 18.9) | 21.5 (12.7 to 36.6) | 1.0 (1.0 to 1.0) |
| 5-11 Years, ST6: Month 19 | 49.8 (29.4 to 84.6) | 52.0 (24.6 to 110.0) | 1.1 (1.0 to 1.3) |
| 5-11 Years, ST6: Month 31 | 16.1 (7.8 to 33.0) | 16.1 (8.1 to 31.9) | 1.4 (0.8 to 2.2) |
| 5-11 Years, ST6: Month 43 | 14.9 (10.8 to 20.5) | 23.4 (14.1 to 39.0) | 1.0 (0.8 to 1.2) |
| 12-17 Years, ST1: Month 19 | 43.4 (25.8 to 73.0) | 78.4 (46.7 to 131.5) | 1.0 (1.0 to 1.0) |
| 12-17 Years, ST1: Month 31 | 25.7 (14.3 to 46.0) | 29.8 (18.2 to 49.0) | 0.9 (0.8 to 1.1) |
| 12-17 Years, ST1: Month 43 | 12.4 (8.0 to 19.2) | 18.1 (11.2 to 29.1) | 1.1 (0.9 to 1.3) |
| 12-17 Years, ST2: Month 19 | 46.2 (27.8 to 76.7) | 73.9 (47.0 to 116.3) | 1.0 (1.0 to 1.0) |
| 12-17 Years, ST2: Month 31 | 19.8 (11.0 to 35.5) | 16.8 (12.0 to 23.6) | 1.0 (1.0 to 1.1) |
| 12-17 Years, ST2: Month 43 | 10.3 (6.8 to 15.8) | 14.4 (8.8 to 23.4) | 1.0 (1.0 to 1.0) |
| 12-17 Years, ST3: Month 19 | 45.0 (27.3 to 74.2) | 70.6 (43.7 to 113.9) | 1.1 (1.0 to 1.2) |
| 12-17 Years, ST3: Month 31 | 18.5 (10.2 to 33.4) | 16.7 (12.6 to 22.3) | 1.0 (0.8 to 1.2) |
| 12-17 Years, ST3: Month 43 | 10.8 (7.3 to 15.9) | 12.8 (8.1 to 20.0) | 1.1 (0.9 to 1.2) |
| 12-17 Years, ST4: Month 19 | 42.4 (26.0 to 69.0) | 68.1 (41.8 to 110.9) | 1.1 (1.0 to 1.2) |
| 12-17 Years, ST4: Month 31 | 22.2 (12.7 to 38.6) | 22.7 (14.8 to 34.9) | 1.1 (0.9 to 1.2) |
| 12-17 Years, ST4: Month 43 | 13.3 (8.8 to 19.9) | 15.1 (9.3 to 24.8) | 1.2 (0.9 to 1.5) |
| 12-17 Years, ST5: Month 19 | 40.0 (24.5 to 65.3) | 71.8 (43.9 to 117.4) | 1.0 (1.0 to 1.1) |
| 12-17 Years, ST5: Month 31 | 21.1 (11.8 to 37.9) | 23.5 (15.1 to 36.5) | 1.2 (0.9 to 1.4) |
| 12-17 Years, ST5: Month 43 | 11.2 (7.4 to 17.1) | 16.3 (10.4 to 25.6) | 1.1 (0.9 to 1.3) |
| 12-17 Years, ST6: Month 19 | 39.1 (24.0 to 63.9) | 59.1 (37.0 to 94.3) | 1.1 (0.9 to 1.2) |
| 12-17 Years, ST6: Month 31 | 21.8 (12.5 to 38.0) | 23.9 (15.6 to 36.5) | 0.9 (0.8 to 1.1) |
| 12-17 Years, ST6: Month 43 | 10.0 (6.7 to 15.1) | 14.4 (8.8 to 23.6) | 1.1 (0.9 to 1.2) |
| 18-65 Years, ST1: Month 19 | 32.2 (24.1 to 42.9) | 23.4 (16.8 to 32.5) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST1: Month 31 | 18.5 (14.1 to 24.4) | 15.1 (11.6 to 19.5) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST1: Month 43 | 12.6 (10.2 to 15.4) | 11.1 (8.5 to 14.5) | 1.1 (0.9 to 1.3) |
| 18-65 Years, ST2: Month 19 | 48.3 (38.1 to 61.2) | 48.5 (36.6 to 64.3) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST2: Month 31 | 16.4 (13.1 to 20.6) | 14.5 (11.7 to 18.0) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST2: Month 43 | 12.1 (9.8 to 14.9) | 11.7 (8.6 to 15.8) | 1.1 (0.9 to 1.3) |
| 18-65 Years, ST3: Month 19 | 44.9 (34.8 to 57.9) | 39.5 (30.4 to 51.5) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST3: Month 31 | 17.0 (13.4 to 21.5) | 13.1 (10.7 to 15.9) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST3: Month 43 | 11.5 (9.6 to 13.8) | 9.5 (7.3 to 12.2) | 1.1 (0.9 to 1.3) |
| 18-65 Years, ST4: Month 19 | 36.0 (27.7 to 46.9) | 29.8 (21.8 to 40.9) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST4: Month 31 | 17.9 (14.0 to 22.8) | 15.7 (12.4 to 19.9) | 1.0 (1.0 to 1.1) |
| 18-65 Years, ST4: Month 43 | 13.0 (10.5 to 16.1) | 10.8 (8.3 to 14.0) | 1.1 (0.9 to 1.3) |
| 18-65 Years, ST5: Month 19 | 37.0 (28.0 to 48.8) | 29.6 (21.6 to 40.5) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST5: Month 31 | 19.2 (15.0 to 24.6) | 14.2 (11.4 to 17.7) | 1.0 (1.0 to 1.0) |
| 18-65 Years, ST5: Month 43 | 13.4 (10.9 to 16.4) | 10.3 (8.0 to 13.4) | 1.1 (0.9 to 1.3) |
| 18-65 Years, ST6: Month 19 | 32.6 (25.3 to 42.1) | 28.3 (20.3 to 39.5) | 1.0 (1.0 to 1.1) |
| 18-65 Years, ST6: Month 31 | 18.2 (14.3 to 23.2) | 12.9 (10.3 to 16.0) | 1.0 (1.0 to 1.1) |
| 18-65 Years, ST6: Month 43 | 11.8 (9.7 to 14.4) | 10.4 (8.0 to 13.5) | 1.1 (0.9 to 1.3) |
Collected over Systematic assessment: local reactions and systemic events were assessed for up to 7 Days after each vaccination; non- systematic assessment: all-cause mortality, SAEs, AESIs were assessed up to Month 48 and other AEs (including non-SAEs) were assessed up to 28 days after each vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: VLA15 | 0/127 (0%) | 0/127 (0%) | 124/127 (97.6%) |
| Group 2: VLA15 + Placebo | 0/112 (0%) | 4/112 (3.6%) | 111/112 (99.1%) |
| Group 3: Placebo | 0/206 (0%) | 14/206 (6.8%) | 145/206 (70.4%) |
| Received Any VLA15 Including Wrong/Missed Vaccination | 1/419 (0.2%) | 14/419 (3.3%) | 403/419 (96.2%) |
| All Participants | 1/625 (0.2%) | 28/625 (4.5%) | 548/625 (87.7%) |
| Event | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/127 | 0/112 | 2/206 | 0/419 | 2/625 |
| ConcussionInjury, poisoning and procedural complications | 0/127 | 1/112 | 0/206 | 1/419 | 1/625 |
| Procedural painInjury, poisoning and procedural complications | 0/127 | 1/112 | 0/206 | 1/419 | 1/625 |
| Major depressionPsychiatric disorders | 0/127 | 1/112 | 0/206 | 1/419 | 1/625 |
| Lumbar radiculopathyNervous system disorders | 0/127 | 1/112 | 0/206 | 1/419 | 1/625 |
| OverdoseInjury, poisoning and procedural complications | 0/127 | 0/112 | 1/206 | 1/419 | 2/625 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/127 | 0/112 | 1/206 | 0/419 | 1/625 |
| Tibia fractureInjury, poisoning and procedural complications | 0/127 | 0/112 | 1/206 | 0/419 | 1/625 |
| Wrist fractureInjury, poisoning and procedural complications | 0/127 | 0/112 | 1/206 | 0/419 | 1/625 |
| Breast cancer stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/127 | 0/112 | 1/206 | 0/419 | 1/625 |
| Event | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Received Any VLA15 Including Wrong/Missed Vaccination | All Participants |
|---|---|---|---|---|---|
| Injection site painGeneral disorders | 122/127 | 110/112 | 80/206 | 396/419 | 476/625 |
| MyalgiaMusculoskeletal and connective tissue disorders | 81/127 | 71/112 | 50/206 | 238/419 | 288/625 |
| HeadacheNervous system disorders | 75/127 | 51/112 | 81/206 | 196/419 | 277/625 |
| Injection site erythemaGeneral disorders | 73/127 | 45/112 | 23/206 | 192/419 | 215/625 |
| Injection site swellingGeneral disorders | 70/127 | 46/112 | 18/206 | 181/419 | 199/625 |
| Injection site indurationGeneral disorders | 62/127 | 46/112 | 16/206 | 174/419 | 190/625 |
| FatigueGeneral disorders | 59/127 | 53/112 | 64/206 | 172/419 | 236/625 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 36/127 | 12/112 | 22/206 | 78/419 | 100/625 |
| NauseaGastrointestinal disorders | 21/127 | 23/112 | 28/206 | 71/419 | 99/625 |
| PyrexiaGeneral disorders | 11/127 | 4/112 | 7/206 | 20/419 | 27/625 |
Full analysis set (FAS) included all participants enrolled who received at least one vaccination. Participants were analyzed according to the study group they had been allocated to, rather than by the actual treatment they received.
| Age, Continuous(Years) | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Total |
|---|---|---|---|---|
| Mean | 28.7 ± 19.09 | 28.9 ± 19.56 | 29.0 ± 19.72 | 28.9 ± 19.43 |
| Sex: Female, Male(Participants) | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Total |
|---|---|---|---|---|
| Female | 112 | 108 | 101 | 321 |
| Male | 96 | 101 | 107 | 304 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 15 | 18 | 56 |
| Not Hispanic or Latino | 185 | 194 | 190 | 569 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: VLA15 | Group 2: VLA15 + Placebo | Group 3: Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 4 | 3 | 6 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 27 | 17 | 24 | 68 |
| White | 172 | 184 | 176 | 532 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 5 | 2 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2021 to primary completion in Mar 2022, 12 months.
Results were first posted in Jun 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VLA15